

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES


Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



(12) UK Patent Application (19) GB (11) 2 302 689 (13) A

(43) Date of A Publication 29.01.1997

(21) Application No 9613003.4

(22) Date of Filing 20.06.1996

(30) Priority Data

(31) 9513118

(32) 28.06.1995

(33) GB

(51) INT CL⁶

C07D 413/06, A61K 31/535, C07D 413/14

(52) UK CL (Edition O)

C2C CAA CLZ CQT C1341 C1450 C1582 C215 C22Y
C220 C248 C25Y C250 C251 C252 C255 C28X C31Y
C311 C32Y C323 C334 C36Y C364 C37Y C373 C464
C613 C620 C650 C672 C694 C697 C699 C80Y C802
U1S S1321 S1328 S2414 S2415 S2416 S2417

(71) Applicant(s)

Merck Sharp & Dohme Limited

(Incorporated in the United Kingdom)

Hertford Road, HODDESDON, Hertfordshire,
EN11 9BU, United Kingdom

(72) Inventor(s)

Jonathan David Moseley

Christopher John Swain

Brian John Williams

(74) Agent and/or Address for Service

I J Hiscock

Merck & Co. Inc, European Patent Department,
Terlings Park, Eastwick Road, HARLOW, Essex,
CM20 2QR, United Kingdom

(56) Documents Cited

None

(58) Field of Search

UK CL (Edition O) C2C
INT CL⁶ C07D
ONLINE: CAS

(54) N-oxides of morpholine derivatives and their use as therapeutic agents


(57) The present invention relates to morpholine derivatives of the formula (I) and pharmaceutically acceptable salts thereof wherein

R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R^{9a}, R^{9b}, X, Y, Z and Het are as defined in the specification;

m is 0 or 1; and

n is 0 or 1, where the sum total of n+m is 1 or 2.

The compounds are of particular use in the treatment of pain, inflammation, migraine, emesis and postherpetic neuralgia.



GB 2 302 689 A

N-OXIDES OF MORPHOLINE DERIVATIVES AND THEIR USE AS
THERAPEUTIC AGENTS

This invention relates to a class of morpholine derivatives which are
5 useful as tachykinin antagonists. More particularly, this invention relates
to the N-oxides of a class of morpholine derivatives which contain an
amine-substituted azo-heterocyclic moiety.

The tachykinins are a group of naturally occurring peptides found
widely distributed throughout mammalian tissues, both within the central
10 nervous system and in peripheral nervous and circulatory systems.

The tachykinins are distinguished by a conserved carboxyl-terminal
sequence:

Phe-X-Gly-Leu-Met-NH₂

At present, there are three known mammalian tachykinins referred
15 to as substance P, neurokinin A (NKA, substance K, neuromedin L) and
neurokinin B (NKB, neuromedin K) (for review see J.E. Maggio, *Peptides*
(1985) 6(suppl. 3), 237-242). The current nomenclature designates the
three tachykinin receptors mediating the biological actions of substance P,
NKA and NKB as the NK₁, NK₂ and NK₃ receptors, respectively.

Evidence for the usefulness of tachykinin receptor antagonists in
pain, headache, especially migraine, Alzheimer's disease, multiple
sclerosis, attenuation of morphine withdrawal, cardiovascular changes,
oedema, such as oedema caused by thermal injury, chronic inflammatory
diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity
25 and other respiratory diseases including allergic rhinitis, inflammatory
diseases of the gut including ulcerative colitis and Crohn's disease, ocular
injury and ocular inflammatory diseases, proliferative vitreoretinopathy,
irritable bowel syndrome and disorders of bladder function including
cystitis and bladder detrusor hyper-reflexia is reviewed in "Tachykinin
30 Receptors and Tachykinin Receptor Antagonists", C.A. Maggi, R.

Patachini, P. Rovero and A. Giachetti, *J. Auton. Pharmacol.* (1993) 13, 23-93.

For instance, substance P is believed *inter alia* to be involved in the neurotransmission of pain sensations [Otsuka *et al*, "Role of Substance P as a Sensory Transmitter in Spinal Cord and Sympathetic Ganglia" in 5 1982 *Substance P in the Nervous System, Ciba Foundation Symposium* 91, 13-34 (published by Pitman) and Otsuka and Yanagisawa, "Does Substance P Act as a Pain Transmitter?" *TIPS* (1987) 8, 506-510], specifically in the transmission of pain in migraine (B.E.B. Sandberg *et al*, 10 *J. Med Chem.*, (1982) 25, 1009) and in arthritis [Levine *et al* in *Science* (1984) 226, 547-549]. Tachykinins have also been implicated in gastrointestinal (GI) disorders and diseases of the GI tract such as inflammatory bowel disease [Mantyh *et al* in *Neuroscience* (1988) 25(3), 15 817-37 and D. Regoli in "Trends in Cluster Headache" Ed. Sicuteri *et al* Elsevier Scientific Publishers, Amsterdam (1987) page 85] and emesis [F. D. Tattersall *et al*, *Eur. J. Pharmacol.*, (1993) 250, R5-R6]. It is also hypothesised that there is a neurogenic mechanism for arthritis in which substance P may play a role [Kidd *et al* "A Neurogenic Mechanism for Symmetrical Arthritis" in *The Lancet*, 11 November 1989 and Grönblad *et* 20 *al*, "Neuropeptides in Synovium of Patients with Rheumatoid Arthritis and Osteoarthritis" in *J. Rheumatol.* (1988) 15(12), 1807-10]. Therefore, substance P is believed to be involved in the inflammatory response in diseases such as rheumatoid arthritis and osteoarthritis, and fibrosis [O'Byrne *et al*, *Arthritis and Rheumatism* (1990) 33, 1023-8]. Other 25 disease areas where tachykinin antagonists are believed to be useful are allergic conditions [Hamelet *et al*, *Can. J. Pharmacol. Physiol.* (1988) 66, 1361-7], immunoregulation [Lotz *et al*, *Science* (1988) 241, 1218-21 and Kimball *et al*, *J. Immunol.* (1988) 141(10), 3564-9], vasodilation, bronchospasm, reflex or neuronal control of the viscera [Mantyh *et al*, 30 *Proc. Natl. Acad. Sci., USA* (1988) 85, 3235-9] and, possibly by arresting or slowing β -amyloid-mediated neurodegenerative changes [Yankner *et al*,


Science (1990) **250**, 279-82] in senile dementia of the Alzheimer type, Alzheimer's disease and Down's Syndrome.

Tachykinin antagonists may also be useful in the treatment of small cell carcinomas, in particular small cell lung cancer (SCLC) [Langdon *et al*, *Cancer Research* (1992) **52**, 4554-7].

Substance P may also play a role in demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis [J. Luber-Narod *et al*, poster *C.I.N.P. XVIIIth Congress*, 28th June-2nd July 1992], and in disorders of bladder function such as bladder detrusor hyper-reflexia (*The Lancet*, 16th May 1992, 1239).


It has furthermore been suggested that tachykinins have utility in the following disorders: depression, dysthymic disorders, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, neuropathy, neuralgia, disorders related to immune enhancement or suppression such as systemic lupus erythematosus (European patent specification no. 0 436 334), ophthalmic disease such as conjunctivitis, vernal conjunctivitis, and the like, and cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis (European patent specification no. 0 394 989).

European patent specification no. 0 577 394 (published 5th January 1994) discloses morpholine and thiomorpholine tachykinin receptor antagonists of the general formula



wherein R¹ is a large variety of substituents;
R² and R³ are inter alia hydrogen;
R⁴ is inter alia

5



R⁵ is inter alia optionally substituted phenyl;

R⁶, R⁷ and R⁸ are a variety of substituents;

10 X is O, S, SO or SO₂;


Y is inter alia O; and

Z is hydrogen or C₁₋₄alkyl.

We have now found a further class of non-peptides which are potent antagonists of tachykinins, especially of substance P.

15 It is desirable that compounds may be administered orally and by injection. Certain compounds have now been discovered which act as potent non-peptide tachykinin antagonists and which, by virtue of their advantageous aqueous solubility, are particularly easily formulated for administration by both the oral and injection routes, for example in
20 aqueous media.

The present invention provides compounds of the formula (I):



wherein

- R¹ is hydrogen, halogen, C₁-alkyl, C₁-alkoxy, CF₃, OCF₃, NO₂, CN,
5 SR^a, SOR^a, SO₂R^a, CO₂R^a, CONR^aR^b, C₂-alkenyl, C₂-alkynyl or C₁-alkyl
substituted by C₁-alkoxy, wherein R^a and R^b each independently represent
hydrogen or C₁-alkyl;
- R² is hydrogen, halogen, C₁-alkyl, CF₃, OCF₃ or C₁-alkoxy
substituted by C₁-alkoxy;
- 10 R³ is hydrogen, halogen, CF₃ or OCF₃;
- R⁴ is hydrogen, halogen, C₁-alkyl, C₁-alkoxy, CF₃, NO₂, CN, SR^a,
SOR^a, SO₂R^a, CO₂R^a, CONR^aR^b, C₂-alkenyl, C₂-alkynyl or C₁-alkyl
substituted by C₁-alkoxy, wherein R^a and R^b are as previously defined;
- R⁵ is hydrogen, halogen, C₁-alkyl, C₁-alkoxy substituted by
15 C₁-alkoxy or CF₃;
- R⁶ is hydrogen, C₁-alkyl, C₃-cycloalkyl, C₃-cycloalkylC₁-alkyl, or
C₂-alkyl substituted by C₁-alkoxy or hydroxy;
- R⁷ is hydrogen, C₁-alkyl, C₃-cycloalkyl, C₃-cycloalkylC₁-alkyl, or
20 C₂-alkyl substituted by one or two substituents selected from C₁-alkoxy,
hydroxy or a 4, 5 or 6 membered heteroaliphatic ring containing one or
two heteroatoms selected from N, O and S;

or R⁶ and R⁷, together with the nitrogen atom to which they are attached, form a saturated or partially saturated heterocyclic ring of 4 to 7 ring atoms, which ring may optionally contain in the ring one oxygen or sulphur atom or a group selected from NR^a, S(O) or S(O)₂ and which ring 5 may be optionally substituted by one or two groups selected from hydroxy, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, oxo, COR^a or CO₂R^a where R^a is as previously defined;

or R⁶ and R⁷ together with the nitrogen atom to which they are attached, form a non-aromatic azabicyclic ring system of 6 to 12 ring 10 atoms;

or Z, R⁶ and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom;

R⁸ is hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C₁₋₄alkoxyC₁₋₄alkyl;

15 R^{9a} and R^{9b} are each independently hydrogen or C₁₋₄alkyl, or R^{9a} and R^{9b} are joined so, together with the carbon atoms to which they are attached, there is formed a C₅₋₇ ring;

Het is a 5- or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =O, =S or a C₁₋₄alkyl group;

20 X is an alkylene chain of 1 to 4 carbon atoms optionally substituted by oxo;

Y is a C₁₋₄alkyl group optionally substituted by hydroxy;

Z is C₁₋₆alkylene or C₃₋₇cycloalkylene;

m is 0 or 1; and

25 n is 0 or 1, where the sum total of n+m is 1 or 2;
and pharmaceutically acceptable salts thereof.

According to an alternative aspect of the present invention, R¹ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, CF₃, NO₂, CN, SR^a, SOR^a, SO₂R^a, CO₂R^a, CONR^aR^b, C₂₋₆alkenyl, C₂₋₆alkynyl or C₁₋₄alkyl substituted by 30 C₁₋₄alkoxy, wherein R^a and R^b each independently represent hydrogen or

$C_{1-4}alkyl$; R^2 is hydrogen, halogen, $C_{1-4}alkyl$, C_1 -alkoxy substituted by C_{1-4} alkoxy or CF_3 ; and R^3 is hydrogen, halogen or CF_3 .

A preferred class of compounds of formula (I) is that wherein R^1 is hydrogen, $C_{1-4}alkyl$, C_1 -alkoxy, halogen or CF_3 .

5 Another preferred class of compounds of formula (I) is that wherein R^2 is hydrogen, $C_{1-4}alkyl$, C_1 -alkoxy, halogen or CF_3 .

Also preferred is the class of compounds of formula (I) wherein R^3 is hydrogen, fluorine, chlorine or CF_3 .

10 A particularly preferred class of compounds of formula (I) is that wherein R^1 is fluorine, chlorine or CF_3 .

Another particularly preferred class of compounds of formula (I) is that wherein R^2 is hydrogen, fluorine, chlorine or CF_3 .

Also particularly preferred is the class of compounds of formula (I) wherein R^3 is hydrogen, fluorine, chlorine or CF_3 .

15 Preferably R^1 and R^2 are in the 3 and 5 positions of the phenyl ring.

More preferably R^1 is 3-fluoro or 3- CF_3 .

More preferably R^2 is 5-fluoro or 5- CF_3 .

More preferably R^3 is hydrogen.

Most preferably R^1 is 3-F or 3- CF_3 , R^2 is 5- CF_3 and R^3 is hydrogen.

20 A further preferred class of compound of formula (I) is that wherein R^4 is hydrogen.


Another preferred class of compounds of formula (I) is that wherein R^5 is hydrogen, fluorine, chlorine or CF_3 .

Preferably R^4 is hydrogen and R^5 is hydrogen or 4-fluoro.

25 Also preferred is the class of compounds of formula (I) wherein R^{9a} and R^{9b} are each independently hydrogen or methyl. Preferably R^{9a} is hydrogen. Preferably R^{9b} is hydrogen. Most preferably R^{9a} and R^{9b} are both hydrogen.

30 A further preferred class of compounds of formula (I) is that wherein m is 1.

From the foregoing it will be appreciated that a particularly apt sub-group of compounds of this invention are those of the formula (Ia) and pharmaceutically acceptable salts thereof:



5

wherein A¹ is fluorine or CF₃;

A² is fluorine or CF₃;

A³ is fluorine or hydrogen;

10 and R⁶, R⁷, X, Y, Z, Het, m and n are as defined in relation to formula (I).

A preferred group Y for compounds of the formulae (I) or (Ia) is the C₁₋₄alkyl group, especially the methyl group.

Where the group NR⁶R⁷ forms a saturated heterocyclic ring of 4 to 7 ring atoms which may optionally contain in the ring one oxygen or 15 sulphur atom or a group selected from NR⁸, S(O) or S(O)₂, suitable heterocyclic groups include azetidinyl, pyrrolidino, piperidino, homopiperidino, piperazino, N-methylpiperazino, morpholino and thiomorpholino.

Suitable substituents on the saturated heterocyclic ring include

20 CH₂OH, CH₂OCH₃, oxo, CHO, CO₂H, CO₂CH₃, and CO₂CH₂CH₃.

When used herein the term "halogen" means fluorine, chlorine, bromine and iodine. The most apt halogen are fluorine and chlorine of which fluorine is preferred.

- When used herein the term "alkyl" or "alkoxy" as a group or part of
5 a group means that the group is straight or branched. Examples of suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy.

- The term "alkenyl" as a group or part of a group means that the
10 group is straight or branched and contains at least one double bond. Examples of suitable alkenyl groups include vinyl and allyl.

- The term "alkynyl" as a group or part of a group means that the group is straight or branched and contains at least one triple bond. An example of a suitable alkynyl group is propargyl.

- 15 Suitable cycloalkyl and cycloalkyl-alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl and cyclobutylmethyl.

- Where the group NR⁶R⁷ represents a heteroaliphatic ring of 4 to 7 ring atoms and said ring is partially saturated, a particularly preferred
20 group is 3-pyrroline.

- Where the group NR⁶R⁷ represents a non-aromatic azabicyclic ring system, such a system may contain between 6 and 12, and preferably between 7 and 10, ring atoms. Suitable rings include
5-azabicyclo[2.1.1]hexyl, 5-azabicyclo[2.2.1]heptyl, 6-azabicyclo[3.2.1]octyl,
25 2-azabicyclo[2.2.2]octyl, 6-azabicyclo[3.2.2]nonyl, 6-azabicyclo[3.3.1]nonyl, 6-azabicyclo[3.2.2]decyl, 7-azabicyclo[4.3.1]decyl, 7-azabicyclo[4.4.1]undecyl and 8-azabicyclo[5.4.1]dodecyl, especially 5-azabicyclo[2.2.1]heptyl and 6-azabicyclo[3.2.1]octyl.

- Where R⁷ represents a C₂₋₄alkyl group substituted by a 5 or 6
30 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S, suitable rings include pyrrolidino, piperidino, piperazino,


morpholino, or thiomorpholino. Particularly preferred are nitrogen containing heteroaliphatic rings, especially pyrrolidino and morpholino rings.

Particularly apt values for X for compounds of the formulae (I) or 5 (Ia) include CH_2 , $\text{CH}(\text{CH}_3)$ and CH_2CH_2 of which the CH_2 group is preferred.

Favourably Het is a 5-membered ring.


In particular, Het may represent a heterocyclic ring selected from:

10




Particularly preferred heterocyclic rings represented by Het- $\text{ZN}(\text{O})_m\text{R}^6\text{R}^7$ are selected from:

15




Most especially, Het- $\text{ZN}(\text{O})_m\text{R}^6\text{R}^7$ may represent a heterocyclic ring selected from:

20




A particularly preferred heterocyclic ring represented by
Het-ZN(O)_mR⁶R⁷ is:



5

One favoured group of compounds of this invention are of the formula (Ib) and pharmaceutically acceptable salts thereof:




10

wherein A¹, A² and A³ are defined in relation to formula (Ia) and wherein
Z, R⁶, R⁷, m and n are as defined in relation to formula (I).

Another favoured group of compounds of the present invention are
of the formula (Ic) and pharmaceutically acceptable salts thereof:

15



wherein A¹, A² and A³ are defined in relation to formula (Ia), Q² is CH or N and Z, R⁶, R⁷, m and n are as defined in relation to formula (I).

5 With respect to compounds of the formulae (I), (Ia), (Ib) and (Ic), Z may be a linear, branched or cyclic group. Favourably Z contains 1 to 4 carbon atoms and most favourably 1 or 2 carbon atoms. A particularly favourable group Z is CH₂.

With respect to compounds of the formulae (I), (Ia), (Ib) and (Ic), R⁶ 10 may aptly be a C₁₋₄alkyl group or a C₂₋₄alkyl group substituted by a hydroxyl or C₁₋₂alkoxy group, R⁷ may aptly be a C₁₋₄alkyl group or a C₁₋₄alkyl group substituted by a hydroxyl or C₁₋₂alkoxy group, or R⁶ and R⁷ may be linked so that, together with the nitrogen atom to which they are attached, they form an azetidinyl, pyrrolidinyl, piperidyl, morpholino, 15 thiomorpholino, piperazino or piperazino group substituted on the nitrogen atom by a C₁₋₄alkyl group or a C₂₋₄alkyl group substituted by a hydroxy or C₁₋₂alkoxy group.


Particularly suitable moieties ZNR⁶R⁷ include those wherein Z is CH₂ or CH₂CH₂ and NR⁶R⁷ is amino, methylamino, dimethylamino, 20 diethylamino, azetidinyl, pyrrolidino and morpholino.

Further preferred moieties represented by ZNR⁶R⁷ are those wherein Z is CH₂ or CH₂CH₂, R⁶ represents hydrogen, C₁₋₄alkyl or C₃₋₆cycloalkyl and R⁷ is C₂₋₄alkyl substituted by one or two substituents

selected from hydroxy, C₁₋₂alkoxy, azetidinyl, pyrrolidino, piperidino, morpholino or thiomorpholino.

In particular, Z is preferably CH₂ and NR⁶R⁷ is preferably dimethylamino, azetidinyl or pyrrolidino, especially dimethylamino.

- 5 According to a further aspect of the present invention, or particularly preferred class of compound is that represented by formula (Id) and pharmaceutically acceptable salts thereof:



10

wherein m and n are as defined in relation to formula (I).

Specific compounds within the scope of the present invention include:

- 15 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino(methyl)-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine;
- 20 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylaminomethyl)-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine N-oxide;
- 20 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino(N-oxide)methyl)-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine N-oxide;

3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-methylthio-5-(trifluoromethyl)phenyl)ethoxy)-4-(5-pyrrolidinomethyl-1,2,3-triazol-4-yl)methylmorpholine N-oxide;

3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-methylthio-5-(trifluoromethyl)phenyl)ethoxy)-4-(5-pyrrolidino(N-oxide)methyl-1,2,3-triazol-4-yl)methylmorpholine N-oxide;

and pharmaceutically acceptable salts thereof.

For use in medicine, the salts of the compounds of formula (I) will be non-toxic pharmaceutically acceptable salts. Other salts may, however,

10 be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts such as those formed with hydrochloric acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable

15 salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.

20

The pharmaceutically acceptable salts of the present invention may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed *in vacuo* or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.

30 The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be


functional derivatives of the compounds of formula (I) which are readily convertible *in vivo* into the required compound of formula (I).
Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs",
5 ed. H. Bundgaard, Elsevier, 1985.

A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug" or "parent molecule") that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug
10 molecule. The transformation *in vivo* may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality.

The present invention includes within its scope solvates of the
15 compounds of formula (I) and salts thereof, for example, hydrates.

The compounds according to the invention have at least three asymmetric centres, and may accordingly exist both as enantiomers and as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present
20 invention.

The preferred compounds of the formula (I), (Ia), (Ib), (Ic) and (Id) will have the 2- and 3- substituent cis and the preferred stereochemistry at the 2-position is that possessed by the compound of Example 1 (i.e. 2-(R)-), the preferred stereochemistry of the 3-position is that possessed by
25 the compound of Example 1 (i.e. 3-(S)), and the preferred stereochemistry of the carbon to which the group Y is attached is either (R) when Y is C₁₋₄alkyl (e.g. methyl) or (S) when Y is C₁₋₄alkyl substituted by hydroxy (e.g. CH₂OH). Thus for example as shown in formula (Ie)



The present invention further provides pharmaceutical compositions comprising one or more compounds of formula (I) in association with a pharmaceutically acceptable carrier.

Preferably the compositions according to the invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or administration by inhalation or insufflation.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a

dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former.

5 The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

10 The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar 15 pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

Preferred compositions for administration by injection include those 20 comprising a compound of formula (I), as the active ingredient, in association with a surface-active agent (or wetting agent or surfactant) or in the form of an emulsion (as a water-in-oil or oil-in-water emulsion).

Suitable surface-active agents include, in particular, non-ionic 25 agents, such as polyoxyethylenesorbitans (e.g. Tween™ 20, 40, 60, 80 or 85) and other sorbitans (e.g. Span™ 20, 40, 60, 80 or 85). Compositions with a surface-active agent will conveniently comprise between 0.05 and 5% surface-active agent, and preferably between 0.1 and 2.5%. It will be appreciated that other ingredients may be added, for example mannitol or other pharmaceutically acceptable vehicles, if necessary.

30 Suitable emulsions may be prepared using commercially available fat emulsions, such as Intralipid™, Liposyn™, Infonutrol™, Lipofundin™

and Lipiphysan™. The active ingredient may be either dissolved in a pre-mixed emulsion composition or alternatively it may be dissolved in an oil (e.g. soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and an emulsion formed upon mixing with a phospholipid (e.g. 5 egg phospholipids, soybean phospholipids or soybean lecithin) and water. It will be appreciated that other ingredients may be added, for example glycerol or glucose, to adjust the tonicity of the emulsion. Suitable emulsions will typically contain up to 20% oil, for example, between 5 and 20%. The fat emulsion will preferably comprise fat droplets between 0.1 10 and 1.0µm, particularly 0.1 and 0.5µm, and have a pH in the range of 5.5 to 8.0.

Particularly preferred emulsion compositions are those prepared by mixing a compound of formula (I) with Intralipid™ or the components thereof (soybean oil, egg phospholipids, glycerol and water).

15 Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above. Preferably the compositions are administered by the oral or nasal 20 respiratory route for local or systemic effect. Compositions in preferably sterile pharmaceutically acceptable solvents may be nebulised by use of inert gases. Nebulised solutions may be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, 25 suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.

The present invention further provides a process for the preparation of a pharmaceutical composition comprising a compound of formula (I), 30 which process comprises bringing a compound of formula (I) into association with a pharmaceutically acceptable carrier or excipient.

The compounds of formula (I) are of value in the treatment of a wide variety of clinical conditions which are characterised by the presence of an excess of tachykinin, in particular substance P, activity. These may include disorders of the central nervous system such as anxiety, depression, psychosis and schizophrenia; epilepsy; neurodegenerative disorders such as dementia, including AIDS related dementia, senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelinating diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) and other neuropathological disorders such as peripheral neuropathy, for example AIDS related neuropathy, diabetic and chemotherapy-induced neuropathy, and postherpetic and other neuralgias; neuronal damage, such as cerebralischemic damage and cerebral edema in cerebrovascular disorders; small cell carcinomas such as small cell lung cancer; respiratory diseases, particularly those associated with excess mucus secretion such as chronic obstructive airways disease, bronchopneumonia, chronic bronchitis, asthma, and bronchospasm; airways diseases modulated by neurogenic inflammation; diseases characterised by neurogenic mucus secretion, such as cystic fibrosis; diseases associated with decreased glandular secretions, including lacrimation, such as Sjögren's syndrome, hyperlipoproteinemas IV and V, hemocromatosis, sarcoidosis, and amyloidosis; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, ocular inflammation, osteoarthritis, rheumatoid arthritis, pruritis and sunburn; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, dry eye syndrome, and the like; ophthalmic conditions associated with cell proliferation such as proliferative vitreoretinopathy; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis; addiction disorders including the withdrawal response produced by chronic treatment with, or abuse of, drugs such as benzodiazepines,

- opiates, cocaine, alcohol and nicotine; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus; gastrointestinal (GI) disorders, including inflammatory disorders, and diseases of the GI tract, such as gastritis, gastroduodenal ulcers, gastric carcinomas, gastric lymphomas, disorders associated with the neuronal control of viscera, ulcerative colitis, Crohn's disease, irritable bowel syndrome and emesis, including acute, delayed, post-operative, late phase or anticipatory emesis such as emesis induced by chemotherapy, radiation, toxins, viral or bacterial infections, pregnancy, vestibular disorders, motion, surgery, migraine, opioid analgesics, and variations in intracranial pressure, in particular, for example, drug or radiation induced emesis or post-operative nausea and vomiting; disorders of bladder function such as cystitis, bladder detrusor hyper-reflexia and incontinence; fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease; and pain or nociception, for example, that attributable to or associated with any of the foregoing conditions, especially the transmission of pain in migraine.

Hence, the compounds of the present invention may be of use in the treatment of physiological disorders associated with excessive stimulation of tachykinin receptors, especially neurokinin-1 receptors, and as neurokinin-1 antagonists for the control and/or treatment of any of the aforementioned clinical conditions in mammals, including humans.

The compounds of formula (I) are also of value in the treatment of a combination of the above conditions, in particular in the treatment of combined post-operative pain and post-operative nausea and vomiting.

The compounds of formula (I) are particularly useful in the treatment of emesis, including acute, delayed, post-operative, late phase or

anticipatory emesis, such as emesis or nausea induced by chemotherapy, radiation, toxins, such as metabolic or microbial toxins, viral or bacterial infections, pregnancy, vestibular disorders, motion, mechanical stimulation, gastrointestinal obstruction, reduced gastrointestinal motility,

5 visceral pain, psychological stress or disturbance, high altitude, weightlessness, opioid analgesics, intoxication, resulting for example from consumption of alcohol, surgery, migraine, and variations in intracranial pressure. Most especially, the compounds of formula (I) are of use in the treatment of emesis induced by antineoplastic (cytotoxic) agents including

10 those routinely used in cancer chemotherapy.

Examples of such chemotherapeutic agents include alkylating agents, for example, nitrogen mustards, ethyleneimine compounds, alkyl sulphonates and other compounds with an alkylating action such as nitrosoureas, cisplatin and dacarbazine; antimetabolites, for example, folic acid, purine or pyrimidine antagonists; mitotic inhibitors, for example, vinca alkaloids and derivatives of podophyllotoxin; and cytotoxic antibiotics.

Particular examples of chemotherapeutic agents are described, for instance, by D. J. Stewart in "*Nausea and Vomiting: Recent Research and Clinical Advances*", Eds. J. Kuucharczyk *et al*, CRC Press Inc., Boca Raton, Florida, USA (1991) pages 177-203, especially page 188.

Commonly used chemotherapeutic agents include cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin and chlorambucil [R. J. Gralla *et al* in *Cancer Treatment Reports* (1984) 68(1), 163-172].

The compounds of formula (I) are also of use in the treatment of emesis induced by radiation including radiation therapy such as in the

treatment of cancer, or radiation sickness; and in the treatment of post-operative nausea and vomiting.

It will be appreciated that the compounds of formula (I) may be presented together with another therapeutic agent as a combined preparation for simultaneous, separate or sequential use for the relief of emesis. Such combined preparations may be, for example, in the form of a twin pack.

A further aspect of the present invention comprises the compounds of formula (I) in combination with a 5-HT₃ antagonist, such as ondansetron, granisetron or tropisetron, or other anti-emetic medicaments, for example, a dopamine antagonist such as metoclopramide or GABA_A receptor agonists such as baclofen. Additionally, a compound of formula (I) may be administered in combination with an anti-inflammatory corticosteroid, such as dexamethasone, triamcinolone, triamcinolone acetonide, flunisolide, budesonide, or others such as those disclosed in US patent nos. 2,789,118, 2,990,401, 3,048,581, 3,126,375, 3,929,768, 3,996,359, 3,928,326 and 3,749,712. Dexamethasone (Decadron™) is particularly preferred. Furthermore, a compound of formula (I) may be administered in combination with a chemotherapeutic agent such as an alkylating agent, antimetabolite, mitotic inhibitor or cytotoxic antibiotic, as described above. In general, the currently available dosage forms of the known therapeutic agents for use in such combinations will be suitable.

When tested in the ferret model of cisplatin-induced emesis described by F. D. Tattersall *et al.*, in *Eur. J. pharmacol.*, (1993) 250, R5-R6, the compounds of the present invention were found to attenuate the retching and vomiting induced by cisplatin.

The compounds of formula (I) are also particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as, for example, neuropathy, such as diabetic and chemotherapy-induced neuropathy, postherpetic and other

neuralgias, asthma, osteoarthritis, rheumatoid arthritis, headache and especially migraine.

The present invention further provides a compound of formula (I) for use in therapy.

5 According to a further or alternative aspect, the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the treatment of physiological disorders associated with

an excess of tachykinins, especially substance P.

The present invention also provides a method for the treatment 10 or prevention of physiological disorders associated with an excess of tachykinins, especially substance P, which method comprises administration to a patient in need thereof of a tachykinin reducing amount of a compound of formula (I) or a composition comprising a compound of formula (I).

15 For the treatment of certain conditions it may be desirable to employ a compound according to the present invention in conjunction with another pharmacologically active agent. For example, for the treatment of respiratory diseases such as asthma, a compound of formula (I) may be used in conjunction with a bronchodilator, such as a β_2 -adrenergic receptor 20 agonist or tachykinin antagonist which acts at NK-2 receptors. The compound of formula (I) and the bronchodilator may be administered to a patient simultaneously, sequentially or in combination.

Likewise, a compound of the present invention may be employed 25 with a leukotriene antagonists, such as a leukotriene D₄ antagonist such as a compound selected from those disclosed in European patent specification nos. 0 480 717 and 0 604 114 and in US patent nos. 4,859,692 and 5,270,324. This combination is particularly useful in the treatment of respiratory diseases such as asthma, chronic bronchitis and cough.

The present invention accordingly provides a method for the 30 treatment of a respiratory disease, such as asthma, which method comprises administration to a patient in need thereof of an effective

amount of a compound of formula (I) and an effective amount of a bronchodilator.

The present invention also provides a composition comprising a compound of formula (I), a bronchodilator, and a pharmaceutically acceptable carrier.

It will be appreciated that for the treatment or prevention of migraine, a compound of the present invention may be used in conjunction with other anti-migraine agents, such as ergotamines or 5-HT₁ agonists, especially sumatriptan.

10 Likewise, for the treatment of behavioural hyperalgesia, a compound of the present invention may be used in conjunction with an antagonist of N-methyl D-aspartate (NMDA), such as dizocilpine.

15 For the treatment or prevention of inflammatory conditions in the lower urinary tract, especially cystitis, a compound of the present invention may be used in conjunction with an antiinflammatory agent such as a bradykinin receptor antagonist.


20 In the treatment of the conditions associated with an excess of tachykinins, a suitable dosage level is about 0.001 to 50 mg/kg per day, in particular about 0.01 to about 25 mg/kg, such as from about 0.05 to about 10 mg/kg per day.

25 For example, in the treatment of conditions involving the neurotransmission of pain sensations, a suitable dosage level is about 0.001 to 25 mg/kg per day, preferably about 0.005 to 10 mg/kg per day, and especially about 0.005 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

30 In the treatment of emesis using an injectable formulation, a suitable dosage level is about 0.001 to 10 mg/kg per day, preferably about 0.005 to 5 mg/kg per day, and especially 0.01 to 1 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

It will be appreciated that the amount of a compound of formula (I) required for use in any treatment will vary not only with the particular compounds or composition selected but also with the route of administration, the nature of the condition being treated, and the age and 5 condition of the patient, and will ultimately be at the discretion of the attendant physician.

According to one general process, the compounds of formula (I) may be prepared from compounds of formula (II)



10


by oxidation of one or both of the nitrogen atoms drawn in formula (II).

The oxidation reaction may be effected using hydrogen peroxide, an alkyl peroxide such as t-butylperoxide or a peroxy acid (peracid) such as 15 m-chloroperbenzoic acid or peracetic acid. Hydrogen peroxide is particularly preferred. The reaction is conveniently effected at room temperature in a solvent such as an ether, for example, tetrahydrofuran, acetonitrile or a chlorinated hydrocarbon, for example, dichloromethane, or an oil, for example, soya bean oil.

20 Where oxidation of the morpholine nitrogen is desired, the reaction is conveniently effected in acidic conditions, for example, using hydrogen peroxide in acetic acid.

Where oxidation of the amine moiety NR^6R^7 is desired, neutral conditions are preferred, for example, using hydrogen peroxide in soya bean oil.

- 5 Compounds of formula (II) may be prepared by a variety of methods, thus, according to intermediate process (A), the compounds of formula (II) may be prepared from compounds of formula (IIIa)




- 10 wherein R^1 , R^2 , R^3 , R^4 , R^5 and Y are as defined in relation to formula (I) by reaction with a compound of formula (IIIb):



- 15 where X is as defined in relation to formula (I), Het' is as defined for the group Het in relation to formula (I) or a precursor therefor and L is a leaving group for example a halogen atom such as bromine or chlorine; and, if Het' is a precursor group, converting it to a group Het (in which process any reactive group may be protected and thereafter deprotected if 20 desired).

This reaction may be performed in conventional manner, for example in an organic solvent such as dimethylformamide in the presence of an acid acceptor such as potassium carbonate.


- 25 According to another process (B), compounds of formula (II) wherein Het represents 1,2,3-triazol-4-yl substituted by $\text{CH}_2\text{NR}^6\text{R}^7$, and X is $-\text{CH}_2-$, may be prepared by reaction of a compound of formula (IV)



(IV)

with an azide, for example, sodium azide in a suitable solvent such as
5 dimethylsulphoxide at a temperature of between 40°C and 100°C, followed by reduction of the carbonyl group adjacent to $\text{-NR}^6\text{R}^7$ using a suitable reducing agent such as lithium aluminium hydride at a temperature between -10°C and room temperature, conveniently at room temperature.

Alternatively, according to a process (C), compounds of formula (II) wherein Het represents 1,2,3-triazol-4-yl substituted by $\text{CH}_2\text{NR}^6\text{R}^7$, and X is $\text{-CH}_2\text{-}$, may be prepared by reaction of a compound of formula (V)




(V)

15 with an amine of formula NHR^6R^7 , in a suitable solvent such as an ether, for example, dioxan, at elevated temperature, for example, between 50°C

and 100°C, in a sealed tube, or the like. This reaction is based upon that described in *Chemische Berichte* (1989) **122**, p. 1963.



According to another process, (D), compounds of formula (II) wherein Het represents 1,3,5-triazine may be prepared by reaction of
5 intermediates of formula (VI):



with an appropriately substituted 1,3,5-triazine.

The reaction is conveniently effected in a suitable organic solvent,
such as acetonitrile, at elevated temperature, such as 80-90°C, preferably
10 about 82°C.

According to a further process, (E), compounds of formula (II)
wherein Het represents 1,2,4-triazine may be prepared by reaction of an
intermediate of formula (VII) with a dicarbonyl compound of formula
(VIII):




15

wherein R³⁵ represents the substituent ZNR⁶R⁷.

The reaction is conveniently effected in a suitable organic solvent, such as an ether, e.g. tetrahydrofuran, conveniently at ambient temperature.

- According to a further process (F), compounds of formula (II) 5 wherein Het represents a substituted 1,2,4-triazolyl group may be prepared by reaction of an intermediate of formula (III) with a compound of formula (IX)




- wherein X is as defined in relation to formula (I), Hal is a halogen atom, 10 for example, bromine, chlorine or iodine and R¹⁸ is H, CONH₂ or OCH₃ (which is converted to an oxo substituent under the reaction conditions), in the presence of a base, followed where necessary by conversion to a compound of formula (I), for example, by reduction of the CONH₂ group to CH₂NH₂.

- 15 Suitable bases of use in the reaction include alkali metal carbonates such as, for example, potassium carbonate. The reaction is conveniently effected in an anhydrous organic solvent such as, for example, anhydrous dimethylformamide, preferably at elevated temperature, such as about 140°C.

- 20 A suitable reducing agent for the group CONH₂ is lithium aluminium hydride, used at between -10°C and room temperature.

According to another process, (G), compounds of formula (II) wherein Het represents thioxotriazolyl may be prepared from intermediates of formula (X)




by reaction with a compound of formula HNCS , in the presence of a base.

Suitable bases of use in the reaction include organic bases such as, for example, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). The reaction is 5 conveniently effected in a suitable organic solvent, such as alcohol, e.g. butanol.

Further details of suitable procedures will be found in the accompanying Examples.

Intermediates of formula (IV) may be prepared from intermediates 10 of formula (IIIa) by reaction with an acetylene compound of formula $\text{HC}\equiv\text{C-CH}_2\text{-Hal}$ in the presence of a base such as potassium carbonate in a suitable solvent such as dimethylformamide, conveniently at room temperature, followed by reaction of the resultant acetylene intermediate with an amide of formula $\text{Hal-CO-NR}^6\text{R}^7$ in the presence of suitable 15 catalysts including bis(triphenylphosphine) palladium(II) chloride, copper(I) iodide and triphenylphosphine in a suitable solvent such as triethylamine, preferably at reflux.

Intermediates of formula (V) may be prepared from a compound of formula (XI)



wherein Hal is a halogen atom, for example, chlorine, bromine or iodine, especially chlorine, by reaction with an azide, for example, sodium azide in a suitable solvent such as dimethylsulphoxide at or below room temperature.

- 5 Compounds of formula (XI) may be prepared by a dropwise addition of an intermediate of formula (IIIa) to a dihaloacetylene of formula Hal-CH₂-C≡C-CH₂-Hal where each Hal is independently chlorine, bromine or iodine, especially chlorine. The reaction is conveniently effected in a
10 suitable solvent such as dimethylformamide in the presence of a base such as potassium carbonate.

Intermediates of formula (VI) may be prepared from intermediates of formula (IIIa) by reaction with a compound of formula Hal-X-C(NH)NH₂, where Hal and X are as previously defined.

- 15 Intermediates of formula (VII) may be prepared from intermediates of formula (IIIa) by reaction with a compound of formula Hal-X-C(NH)NNH-Boc, wherein Hal and X are as previously defined and Boc stands for t-butoxycarbonyl, followed by deprotection under acidic conditions.

- 20 Compounds of formula (VIII) are commercially available or may be prepared from commercially available compounds by known methods.

Compounds of formula (IX) may be prepared as described in *J. Med. Chem.*, (1984) 27, 849.


Intermediates of formula (X) may be prepared from the corresponding ester by treatment with hydrazine. The reaction is conveniently effected in a suitable organic solvent, such as an alcohol, for example, ethanol, at elevated temperature.

5 For compounds wherein Het is a heterocycle bearing the ZNR^6R^7 group where Z is CH_2 , certain favoured compounds of formula (I) may be prepared from a corresponding compound with a hydrogen atom in place of the ZNR^6R^7 . Thus, for example a compound of the formula (I) wherein Het is an imidazolinone group carrying a $\text{CH}_2\text{NR}^6\text{R}^7$ moiety may be
10 prepared from a corresponding compound lacking the $\text{CH}_2\text{NR}^6\text{R}^7$ moiety by reaction with formaldehyde and an amine NHR^6R^7 under conventional Mannich reaction conditions, for example in methanol with heating. If desired a pre-formed reagent such as $\text{R}^6\text{R}^7\text{N}^+ = \text{CH}_2\text{.I}^-$ may be employed and a tertiary amine such as triethylamine used as acid acceptor.

15 Alternatively a compound of formula (I) wherein Het is an imidazolinone group lacking a $\text{CH}_2\text{NR}^6\text{R}^7$ may be reacted with paraformaldehyde and an amine for example a secondary amine such as pyrrolidine to give a compound wherein the imidazolinone ring is substituted by $\text{CH}_2\text{NR}^6\text{R}^7$ where R^6 , R^7 and the nitrogen atom to which
20 they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom or a second nitrogen atom which will be part of a NR^8 moiety, where R^8 is as previously defined.

25 This reaction may be performed in a conventional manner, for instance, in a suitable solvent such as an alcohol, for example, methanol at an elevated temperature up to the boiling point of the solvent.

A further alternative method for the preparation of certain compounds of formula (II) involves the reaction of an intermediate of formula (IIIa) as defined above with one of the compounds of formula (XII):




wherein each LG, which may be the same or different, is a leaving group,
such as an alkyl- or arylsulphonyloxy group (e.g. mesylate or tosylate) or,
5 in particular, a halogen atom, (e.g. bromine, chlorine or iodine) and X and
Z are as defined in formula (I), followed by reaction of the resultant
compound with an amine NHR^6R^7 to complete the ZNR^6R^7 moiety.

This reaction is conveniently effected in an organic solvent such as
dimethylformamide in the presence of an acid acceptor such as potassium
10 carbonate.

It will be appreciated that, where necessary, reactive groups may be
protected, thus for example, the NH groups of an imidazolinone of formula
(XIIa) may be protected by any suitable amine protecting group such as an
acetyl group.

15 The compounds of the formula (IIIa) may be prepared as shown in
the following Scheme in which Ar^1 represents the R^1 , R^2 , R^3 substituted
phenyl group; Ar^2 represents the R^4 , R^5 substituted phenyl group and Ph
represents phenyl:



L-Selectride is lithium tri-sec-butylborohydride.

The following references describe methods which may be applied by the skilled worker to the chemical synthesis set forth above once the skilled worker has read the disclosure herein:

- (I) D.A. Evans *et al.*, *J. Am. Chem. Soc.*, (1990) 112, 4011.
- (ii) I. Yanagisawa *et al.*, *J. Med. Chem.*, (1984) 27, 849.
- (iii) R. Duschinsky *et al.*, *J. Am. Chem. Soc.*, (1948) 70, 657.
- (iv) F.N. Tebbe *et al.*, *J. Am. Chem. Soc.*, (1978) 100, 3611.
- (v) N.A. Petasis *et al.*, *J. Am. Chem. Soc.*, (1990) 112, 6532.
- (vi) K. Takai *et al.*, *J. Org. Chem.*, (1987) 52, 4412.

10

The Examples disclosed herein produce predominantly the preferred isomers. The unfavoured isomers are also produced as minor components. If desired they may be isolated and employed to prepare the

various stereoisomers in conventional manner, for example chromatography using an appropriate column. However, the skilled worker will appreciate that although the Examples have been optimized to the production of the preferred isomers, variation in solvent, reagents, 5 chromatography etc can be readily employed to yield the other isomers.

It will be appreciated that compounds of the formula (I) wherein Het contains an =O or =S substituent can exist in tautomeric forms. All such tautomeric forms and mixtures thereof are included within this invention. Most aptly the =O or =S substituent in Het is the =O 10 substituent.

Where they are not commercially available, the intermediates of formula (III) above may be prepared by the procedures described in the accompanying Examples or by alternative procedures which will be readily apparent to one skilled in the art.

15 During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and 20 P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The exemplified compounds of this invention were tested by the methods set out at pages 36 to 39 of International Patent Specification No. 25 WO 93/01165. The compounds or, in the case of prodrugs, the parent compounds, were found to be active with IC₅₀ at the NK₁ receptor of less than 100nM on said test method.

30 The following Examples illustrate the preparation of compounds according to the present invention:

DESCRIPTION 1

(S)-(4-Fluorophenyl)glycine

Via Chiral Synthesis:

5 Step A: 3-(4-Fluorophenyl)acetyl-4-(S)-benzyl-2-oxazolidinone

An oven-dried, 1 L 3-necked flask, equipped with a septum, nitrogen inlet, thermometer, and a magnetic stirring bar, was flushed with nitrogen and charged with a solution of 5.09g (33.0mmol) of 4-fluorophenylacetic acid in 100ml of anhydrous ether. The solution was 10 cooled to -10°C and treated with 5.60ml (40.0mmol) of triethylamine followed by 4.30ml (35.0mmol) of trimethylacetyl chloride. A white precipitate formed immediately. The resulting mixture was stirred at -10°C for 40 minutes, then cooled to -78°C.

An oven-dried, 250ml round bottom flask, equipped with a septum 15 and a magnetic stirring bar, was flushed with nitrogen and charged with a solution of 5.31g (30.0mmol) of 4-(S)-benzyl-2-oxazolidinone in 40ml of dry THF. The solution was stirred in a dry ice/acetone bath for 10 minutes, then 18.8ml of 1.6M n-butyllithium solution in hexanes was slowly added. After 10 minutes, the lithiated oxazolidinone solution was added, via 20 cannula, to the above mixture in the 3-necked flask. The cooling bath was removed from the resulting mixture and the temperature was allowed to rise to 0°C. The reaction was quenched with 100ml of saturated aqueous ammonium chloride solution, transferred to a 1l flask, and the ether and THF were removed *in vacuo*. The concentrated mixture was partitioned 25 between 300ml of methylene chloride and 50ml of water and the layers were separated. The organic layer was washed with 100ml of 2N aqueous hydrochloric acid solution, 300ml of saturated aqueous sodium bicarbonate solution, dried over magnesium sulfate and concentrated *in vacuo*. Flash chromatography on 400g of silica gel using 3:2 v/v 30 hexanes/ether as the eluant afforded 8.95g of an oil that slowly solidified on standing. Recrystallisation from 10:1 hexanes/ether afforded 7.89g

(83%) of the title compound as a white solid: mp 64-66°C. MS (FAB): m/z 314 (M⁺+H, 100%), 177 (M-ArCH₂CO+H, 85%). ¹H NMR (400MHz, CDCl₃) δ 2.76 (1H, dd, J=13.2, 9.2Hz), 3.26 (dd, J=13.2, 3.2Hz), 4.16-4.34 (4H, m), 4.65 (1H, m), 7.02-7.33 (9H, m).

- 5 Analysis Calcd. for C₁₁H₁₄FNO₃: C, 69.00; H, 5.15; N, 4.47; F, 6.06;
Found: C, 68.86; H, 5.14; N, 4.48; F, 6.08%.

Step B: 3-((S)-Azido-(4-fluorophenyl))acetyl-4-(S)-benzyl-2-oxazolidinone

An oven-dried, 1l 3-necked flask, equipped with a septum, nitrogen inlet, thermometer, and a magnetic stirring bar, was flushed with nitrogen and charged with a solution of 58.0ml of 1M potassium bis(trimethylsilyl)amide solution in toluene and 85ml of THF and was cooled to -78°C. An oven-dried 250ml round-bottomed flask, equipped with a septum and a magnetic stirring bar, was flushed with nitrogen and charged with a solution of 7.20g (23.0mmol) of 3-(4-fluorophenyl)acetyl-4-(S)-benzyl-2-oxazolidinone (from Step A) in 40ml of THF. The acyl oxazolidinone solution was stirred in a dry ice/acetone bath for 10 minutes, then transferred, via cannula, to the potassium bis(trimethylsilyl)amide solution at such a rate that the internal temperature of the mixture was maintained below -70°C. The acyl oxazolidinone flask was rinsed with 15ml of THF and the rinse was added, via cannula, to the reaction mixture and the resulting mixture was stirred at -78°C for 30 minutes. An oven-dried, 250ml round-bottomed flask, equipped with a septum and a magnetic stirring bar, was flushed with nitrogen and charged with a solution of 10.89g (35.0mmol) of 2,4,6-triisopropylphenylsulfonyl azide in 40ml of THF. The azide solution was stirred in a dry ice/acetone bath for 10 minutes, then transferred, via cannula, to the reaction mixture at such a rate that the internal temperature of the mixture was maintained below -70°C. After 2 minutes, the reaction was quenched with 6.0ml of glacial acetic acid, the cooling bath was removed and the mixture was stirred at room temperature for 18

- hours. The quenched reaction mixture was partitioned between 300ml of ethyl acetate and 300ml of 50% saturated aqueous sodium bicarbonate solution. The organic layer was separated, dried over magnesium sulfate, and concentrated *in vacuo*. Flash chromatography on 500g of silica gel
- 5 using 2:1 v/v, then 1:1 v/v hexanes/methylene chloride as the eluant afforded 5.45g (67%) of the title compound as an oil. IR Spectrum (neat, cm^{-1}): 2104, 1781, 1702. ^1H NMR (400MHz, CDCl_3) δ 2.86 (1H, dd, $J=13.2$, 9.6Hz), 3.40 (1H, dd, $J=13.2$, 3.2Hz), 4.09-4.19 (2H, m), 4.62-4.68 (1H, m), 6.14 (1H, s), 7.07-7.47 (9H, m).
- 10 Analysis Calcd. for $\text{C}_{18}\text{H}_{15}\text{FN}_4\text{O}_3$: C 61.01; H, 4.27; N, 15.81; F, 5.36;
Found: C, 60.99; H, 4.19; N, 15.80; F, 5.34%.

Step C: (S)-Azido-(4-fluorophenyl)acetic acid

- A solution of 5.40g (15.2mmol) of 3-((S)-azido-(4-fluorophenyl))acetyl-4-(S)-benzyl-2-oxazolidinone (from Step B) in 200ml of 3:1 v/v THF/water was stirred in an ice bath for 10 minutes. 1.28g (30.4mmol) of lithium hydroxide monohydrate was added in one portion and the resulting mixture was stirred cold for 30 minutes. The reaction mixture was partitioned between 100ml of methylene chloride and 100ml
- 15 of 25% saturated aqueous sodium bicarbonate solution and the layers were separated. The aqueous layer was washed with 2 x 100ml of methylene chloride and acidified to pH 2 with 2N aqueous hydrochloric acid solution. The resulting mixture was extracted with 2 x 100ml of ethyl acetate; the extracts were combined, washed with 50ml of saturated
- 20 aqueous sodium chloride solution, dried over magnesium sulfate, and concentrated *in vacuo* to afford 2.30g (77%) of the title compound as an oil that was used in the following step without further purification. IR Spectrum (neat, cm^{-1}): 2111, 1724. ^1H NMR (400MHz, CDCl_3) δ 5.06 (1H, s), 7.08-7.45 (4H, m), 8.75 (1H, br s).

Step D: (S)-(4-Fluorophenyl)glycine

A mixture of 2.30g (11.8mmol) of (S)-azido-(4-fluorophenyl)acetic acid (from Step C), 2.50mg 10% palladium on carbon catalyst and 160ml 3:1 v/v water/acetic acid was stirred under an atmosphere of hydrogen for 5 18 hours. The reaction mixture was filtered through Celite and the flask and filter cake were rinsed well with about 1 litre of 3:1 v/v water/acetic acid. The filtrate was concentrated *in vacuo* to about 50ml of volume. 300ml of toluene was added and the mixture concentrated to afford a solid. The solid was suspended in 1:1 v/v methanol/ether, filtered and dried to 10 afford 1.99g (100%) of the title compound. ^1H NMR (400MHz, $\text{D}_2\text{O} + \text{NaOD}$) δ 3.97 (1H, s), 6.77 (2H, app t, $J=8.8\text{Hz}$), 7.01 (2H, app t, $J=5.6\text{Hz}$).

Via Resolution:

Step A' (4-Fluorophenyl)acetyl chloride

15 A solution of 150g (0.974mol) of 4-(fluorophenyl)acetic acid and 1ml of N,N-dimethylformamide in 500ml of toluene at 40°C was treated with 20ml of thionyl chloride and heated to 40°C. An additional 61.2ml of thionyl chloride was added dropwise over 1.5 hours. After the addition, the solution was heated at 50°C for 1 hour, the solvent was removed *in* 20 *vacuo* and the residual oil was distilled at reduced pressure (1.5mmHg) to afford 150.4g (89.5%) of the title compound, bp = 68-70°C.

Step B': Methyl 2-bromo-3-(4-fluorophenyl)acetate

A mixture of 150.4g (0.872mol) of 4-(fluorophenyl)acetyl chloride (from Step A') and 174.5g (1.09mol) of bromine was irradiated at 40-50°C with a quartz lamp for 5 hours. The reaction mixture was added dropwise to 400ml of methanol and the solution was stirred for 16 hours. The solvent was removed *in vacuo* and the residual oil was distilled at reduced pressure (1.5mmHg) to afford 198.5g (92%) of the title compound, bp = 30 106-110°C.

Step C': Methyl (\pm)-(4-fluorophenyl)glycine

A solution of 24.7g (0.1mol) of methyl 2-bromo-2-(4-fluorophenyl)acetate (from Step B') and 2.28g (0.01mol) of benzyl triethylammonium chloride in 25ml of methanol was treated with 6.8g

- 5 (0.105mol) of sodium azide and the resulting mixture was stirred for 20 hours at room temperature. The reaction mixture was filtered; the filtrate was diluted with 50ml of methanol and hydrogenated in the presence of 0.5g of 10% Pd/C at 50 psi for 1 hour. The solution was filtered and the solvent removed *in vacuo*. The residue was partitioned between 10%
10 aqueous sodium carbonate solution and ethyl acetate. The organic phase was washed with water, saturated aqueous sodium chloride solution dried over magnesium sulfate and concentrated *in vacuo* to afford 9.8g of the title compound as an oil.

15 Step D': Methyl (S)-(4-fluorophenyl)glycinate

A solution of 58.4g of methyl (\pm) 4-(fluorophenyl)glycinate (from Step C') in 110ml of 7:1 v/v ethanol/water was mixed with a solution of 28.6g (0.0799mol) of O,O'-(+)-dibenzoyltartaric acid ((+)-DBT) (28.6g, 0.0799mol) in 110ml of 7:1 v/v ethanol:water and the resulting solution

- 20 was allowed to age at room temperature. Ethyl acetate (220ml) was added after crystallisation was complete and the resulting mixture was cooled to -20°C and filtered to afford 32.4g of methyl (S)-(4-fluorophenyl)glycinate, (+)-DBT salt (ee = 93.2%). The mother liquors were concentrated *in vacuo* and the free base was liberated by partitioning between ethyl acetate and
25 aqueous sodium carbonate solution. A solution of free base, so obtained, in 110ml of 7:1 v/v ethanol/water was mixed with a solution of 28.6g (0.0799mol) of O,O'-(+)-dibenzoyltartaric acid ((+)-DBT) (28.6g, 0.0799mol) in 110ml of 7:1 v/v ethanol:water and the resulting solution was allowed to age at room temperature. Ethyl acetate (220ml) was added after
30 crysallisation was complete and the resulting mixture was cooled to -20°C and filtered to afford 47.0g of methyl (R)-(4-fluorophenyl)glycinate,

(-) -DBT salt (ee = 75.8%). Recycling of the mother liquors and addition of (+)-DBT gave a second crop of 7.4g of (S)-(4-fluorophenyl)glycinate, (+)-DBT salt (ee = 96.4%). The two crops of the (S)-amino ester (39.8g) were combined in 200ml of 7:1 v/v ethanol/water, heated for 30 minutes
5 and cooled to room temperature. Addition of ethyl acetate, cooling, and filtration afforded 31.7g of (S)-(4-fluorophenyl)glycinate, (+)-DBT salt (ee > 98%). Enantiomeric excess was determined by chiral HPLC (Crownpak CR(+)) 5% MeOH in aq HClO₄ pH 2 1.5ml/min 40°C 200nm).

A mixture of 17.5g of (S)-(4-fluorophenyl)glycinate, (+)-DBT salt
10 and 32ml of 5.5N HCl (32ml) was heated at reflux for 1.5 hours. The reaction mixture was concentrated *in vacuo* and the residue was dissolved in 40ml of water. The aqueous solution was washed (3 x 30ml of ethyl acetate) and the layers were separated. The pH of the aqueous layer was adjusted to 7 using ammonium hydroxide and the precipitated solid was
15 filtered to afford 7.4g of the title compound (ee = 98.8%).

DESCRIPTION 2

4-Benzyl-3-(S)-(4-fluorophenyl)-2-morpholinone

20 Step A: N-Benzyl-(S)-(4-fluorophenyl)glycine

A solution of 1.87g (11.05mmol) of (S)-(4-fluorophenyl)-glycine (from Description 1) and 1.12ml (11.1mmol) of benzaldehyde in 11.1ml of 1N aqueous sodium hydroxide solution and 11ml of methanol at 0°C was treated with 165mg (4.4mmol) of sodium borohydride. The cooling bath
25 was removed and the resulting mixture was stirred at room temperature for 30 minutes. Second portions of benzaldehyde (1.12ml (11.1mmol)) and sodium borohydride (165mg (4.4mmol)) were added to the reaction mixture and stirring was continued for 1.5hours. The reaction mixture was partitioned between 100ml of ether and 50ml of water and the layers were
30 separated. The aqueous layer was separated and filtered to remove a small amount of insoluble material. The filtrate was acidified to pH 5

with 2N aqueous hydrochloric acid solution and the solid that had precipitated was filtered, rinsed well with water, then ether, and dried to afford 1.95g of the title compound. ^1H NMR (400MHz, $\text{D}_2\text{O} + \text{NaOD}$) δ 3.33 (2H, AB q, $J=8.4\text{Hz}$), 3.85 (1H, s), 6.79-7.16 (4H, m).

5

Step B: 4-Benzyl-3-(S)-(4-fluorophenyl)-2-morpholinone

A mixture of 1.95g (7.5mmol) of N-benzyl (S)-(4-fluorophenyl)glycine, 3.90ml (22.5mmol) of N,N-diisopropyl-ethylamine, 6.50ml (75.0mmol) of 1,2-dibromoethane and 40ml of N,N-dimethylformamide was stirred at 100°C for 20 hours (dissolution of all solids occurred on warming). The reaction mixture was cooled and concentrated *in vacuo*. The residue was partitioned between 250ml of ether and 100ml of 0.5N potassium hydrogen sulfate solution and the layers were separated. The organic layer was washed with 100ml of saturated aqueous sodium bicarbonate solution, 3 x 150ml of water, dried over magnesium sulfate, and concentrated *in vacuo*. Flash chromatography on 125g of silica gel using 3:1 v/v hexanes/ether as the eluant afforded 1.58g (74%) of the title compound as an oil. ^1H NMR (400MHz, CDCl_3) δ 2.65 (1H, dt, $J=3.2, 12.8\text{Hz}$), 3.00 (1H, dt, $J=12.8, 2.8\text{Hz}$), 3.16 (1H, d, $J=13.6\text{Hz}$), 3.76 (1H, d, $J=13.6\text{Hz}$), 4.24 (1H, s), 4.37 (1H, dt, $J=13.2, 3.2\text{Hz}$), 4.54 (1H, dt, $J=2.8, 13.2\text{Hz}$), 7.07-7.56 (9H, m).

DESCRIPTION 3

4-Benzyl-2-(R)-(3,5-bis(trifluoromethyl)benzoyloxy)-3-(S)-(4-fluorophenyl)morpholine

A solution of 2.67g (10.0mmol) of 4-benzyl-3-(S)-(4-fluorophenyl)-2-morpholinone (Description 2) in 40ml of dry THF was cooled to -78°C. The cold solution was treated with 12.5ml of 1.0M L-Selectride® solution in THF, maintaining the internal reaction temperature below -70°C. The resulting solution was stirred cold for 45 minutes and the reaction was charged with 3.60ml(20.0mmol) of 3,5-bis(trifluoromethyl)benzoyl

chloride. The resulting yellow mixture was stirred cold for 30 minutes and the reaction was quenched with 50ml of saturated aqueous sodium bicarbonate solution. The quenched mixture was partitioned between 300ml of ether and 50ml of water and the layers were separated. The 5 organic layer was dried over magnesium sulfate. The aqueous layer was extracted with 300ml of ether; the extract was dried and combined with the original organic layer. The combined organics were concentrated *in vacuo*. Flash chromatography on 150g of silica gel using 37:3 v/v hexanes/ether as the eluant afforded 4.06g (80%) of the title compound as a solid.

10 ^1H NMR (200MHz, CDCl_3) δ 2.50 (1H, dt, $J=3.4, 12.0\text{Hz}$), 2.97 (1H, app d, $J=12.0\text{Hz}$), 2.99 (1H, d, $J=13.6\text{Hz}$), 3.72-3.79 (1H, m), 3.82 (1H, d, $J=2.6\text{Hz}$), 4.00 (1H, d, $J=13.6\text{Hz}$), 4.20 (dt, $J=2.4, 11.6\text{Hz}$), 6.22 (1H, d, $J=2.6\text{Hz}$), 7.22, 7.37 (7H, m), 7.57 (2H, app d, $J=6.8\text{Hz}$), 8.07 (1H, s), 8.47 (2H, s). MS (FAB) m/z 528 ($M+\text{H}$, 25%), 270 (100%).

15 Analysis Calcd. for $\text{C}_{26}\text{H}_{20}\text{F}_7\text{NO}_3$: C, 59.21; H, 3.82; N, 2.66; F, 25.21;
Found: C, 59.06; H, 4.05; N, 2.50; F, 25.18%.

DESCRIPTION 4

20 4-Benzyl-2-(R)-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine

Step A: Dimethyl titanocene

A solution of 2.49g (10.0mmol) of titanocene dichloride in 50ml of ether in the dark at 0°C was treated with 17.5ml of 1.4M methylolithium 25 solution in ether maintaining the internal temperature below 5°C . The resulting yellow/orange mixture was stirred at room temperature for 30 minutes and the reaction was quenched by slowly adding 25g of ice. The quenched reaction mixture was diluted with 50ml of ether and 25ml of water and the layers were separated. The organic layer was dried over 30 magnesium sulfate and concentrated *in vacuo* to afford 2.03g (98%) of the title compound as a light-sensitive solid. The dimethyl titanocene could be

stored as a solution in toluene at 0°C for at least 2 weeks without apparent chemical degradation. ^1H NMR (200MHz, CDCl_3) δ -0.15 (6H, s), 6.06 (10H, s).

5 Step B: 4-Benzyl-2-(R)-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine

A solution of the compound of Description 3 (2.50g, 4.9mmol) and 2.50g (12.0mmol) of dimethyl titanocene (from Step A) in 35ml of 1 litre v/v THF/toluene was stirred in an oil bath at 80°C for 16 hours. The reaction mixture was cooled and concentrated *in vacuo*. Flash chromatography on 150g of silica gel using 3:1 v/v hexanes/methylene chloride as the eluant afforded 1.71g (69%) of the title compound as a solid. An analytical sample was obtained via recrystallisation from isopropanol: ^1H NMR (400MHz, CDCl₃) δ 2.42 (1H, dt, J=3.6, 12.0Hz), 2.90 (1H, app d, J=12.0Hz), 2.91 (1H, d, J=13.6Hz), 3.62-3.66 (1H, m), 3.72 (1H, d, J=2.6Hz), 3.94 (1H, d, J=13.6Hz), 4.09 (1H, dt, J=2.4, 12.0Hz), 4.75 (1H, d, J=3.2Hz), 4.82 (1H, d, J=3.2Hz), 5.32 (1H, d, J=2.6Hz), 7.09 (2H, t, J=8.8Hz), 7.24-7.33 (5H, m), 7.58-7.62 (2H, m), 7.80 (1H, s), 7.90 (2H, s); MS (FAB) 526 (M+H, 75%), 270 (100%).

DESCRIPTION 5

2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine

The compound of Description 4 (4.0g) was dissolved in ethyl acetate (50ml) and isopropanol (16ml). To this solution was added palladium on charcoal (1.5g) and the mixture was hydrogenated at 40 psi for 36h. The catalyst was removed by filtration through Celite and the solvents were removed *in vacuo*. The residue was purified by flash chromatography on silica using 100% ethyl acetate and then 1-10% methanol in ethyl acetate.

This afforded isomer A 500mg (15%) and isomer B 2.6g (80%) as clear oils
- isomer B crystallised on standing. For the title compound: ^1H NMR
(400MHz, CDCl_3) δ 1.16 (3H, d, $J=6.8\text{MHz}$), 1.80 (1H, br s), 3.13 (1H, dd,
 $J=3.2, 12.4\text{Hz}$), 3.23 (1H, dt, $J=3.6, 12.4\text{Hz}$), 3.63 (1H, dd, $J=2.4, 11.2\text{Hz}$),
5 4.01 (1H, d, $J=2.4\text{Hz}$), 4.13 (1H, dt, $J=3.2, 12.0\text{Hz}$), 4.42 (1H, d, $J=2.4\text{Hz}$),
4.19 (1H, q, $J=6.8\text{Hz}$), 7.04-7.09 (2H, m), 7.27-7.40 (4H, m), 7.73 (1H, s);
MS (FAB) 438 ($M+\text{H}$, 75%), 180 (100%).
HCl salt formation. To a solution of the free base (0.77g) in diethyl ether
(10ml) was added 1M-HCl in methanol (1.75ml). The solution was
10 evaporated to dryness and on addition of diethyl ether crystals formed.
The solution was filtered and the residue washed with diethyl ether to
give the title compound hydrochloride salt mp 248-250°C.
Analysis Calcd. for $\text{C}_{20}\text{H}_{18}\text{F}_7\text{NO}_2\text{HCl}$: C, 50.70; H, 4.04; N, 2.96; Cl, 7.48;
Found: C, 50.46; H, 3.85; N, 3.01; Cl, 7.31%.

15

DESCRIPTION 6

4-Benzyl-3-(S)-(4-fluorophenyl)-2-(R)-(3-fluoro-5-(trifluoromethyl)
benzoyloxy)morpholine
The title compound was prepared from the reaction of the compound
20 of Description 2 with 3-fluoro-5-(trifluoromethyl)benzoyl chloride
according to the procedure illustrated in Description 3. ^1H NMR
(360MHz, CDCl_3) δ 2.50 (1H, dt, $J=3.3, 12.0\text{Hz}$), 2.96 (1H, d, $J=12.0\text{Hz}$),
2.98 (1H, d, $J=13.6\text{Hz}$), 3.75 (1H, dd, $J=1.7, 11.5\text{Hz}$), 3.80 (1H, d,
 $J=2.5\text{Hz}$), 3.92 (1H, d, $J=13.6\text{Hz}$), 4.19 (1H, dt, $J=2.1, 12.0\text{Hz}$), 6.20 (1H, d,
25 $J=2.5\text{Hz}$), 6.99 (2H, t, $J=8.7\text{Hz}$), 7.2-7.37 (5H, m), 7.51-7.55 (3H, m), 7.89
(1H, d, $J=8.4\text{Hz}$), 8.09 (1H, s). MS (Cl^+) m/z 478 (M^++1 , 100%).
Analysis Calcd. for $\text{C}_{25}\text{H}_{20}\text{F}_5\text{NO}_3$: C, 62.88; H, 4.23; N, 2.93;
Found: C, 62.59; H, 4.03; N, 3.07%.

30

¹⁰ ¹⁵ ²⁰ ²⁵ ³⁰ ³⁵ ⁴⁰ ⁴⁵ ⁵⁰ ⁵⁵ ⁶⁰ ⁶⁵ ⁷⁰ ⁷⁵ ⁸⁰ ⁸⁵ ⁹⁰ ⁹⁵ ¹⁰⁰ ¹⁰⁵ ¹¹⁰ ¹¹⁵ ¹²⁰ ¹²⁵ ¹³⁰ ¹³⁵ ¹⁴⁰ ¹⁴⁵ ¹⁵⁰ ¹⁵⁵ ¹⁶⁰ ¹⁶⁵ ¹⁷⁰ ¹⁷⁵ ¹⁸⁰ ¹⁸⁵ ¹⁹⁰ ¹⁹⁵ ²⁰⁰ ²⁰⁵ ²¹⁰ ²¹⁵ ²²⁰ ²²⁵ ²³⁰ ²³⁵ ²⁴⁰ ²⁴⁵ ²⁵⁰ ²⁵⁵ ²⁶⁰ ²⁶⁵ ²⁷⁰ ²⁷⁵ ²⁸⁰ ²⁸⁵ ²⁹⁰ ²⁹⁵ ³⁰⁰ ³⁰⁵ ³¹⁰ ³¹⁵ ³²⁰ ³²⁵ ³³⁰ ³³⁵ ³⁴⁰ ³⁴⁵ ³⁵⁰ ³⁵⁵ ³⁶⁰ ³⁶⁵ ³⁷⁰ ³⁷⁵ ³⁸⁰ ³⁸⁵ ³⁹⁰ ³⁹⁵ ⁴⁰⁰ ⁴⁰⁵ ⁴¹⁰ ⁴¹⁵ ⁴²⁰ ⁴²⁵ ⁴³⁰ ⁴³⁵ ⁴⁴⁰ ⁴⁴⁵ ⁴⁵⁰ ⁴⁵⁵ ⁴⁶⁰ ⁴⁶⁵ ⁴⁷⁰ ⁴⁷⁵ ⁴⁸⁰ ⁴⁸⁵ ⁴⁹⁰ ⁴⁹⁵ ⁵⁰⁰ ⁵⁰⁵ ⁵¹⁰ ⁵¹⁵ ⁵²⁰ ⁵²⁵ ⁵³⁰ ⁵³⁵ ⁵⁴⁰ ⁵⁴⁵ ⁵⁵⁰ ⁵⁵⁵ ⁵⁶⁰ ⁵⁶⁵ ⁵⁷⁰ ⁵⁷⁵ ⁵⁸⁰ ⁵⁸⁵ ⁵⁹⁰ ⁵⁹⁵ ⁶⁰⁰ ⁶⁰⁵ ⁶¹⁰ ⁶¹⁵ ⁶²⁰ ⁶²⁵ ⁶³⁰ ⁶³⁵ ⁶⁴⁰ ⁶⁴⁵ ⁶⁵⁰ ⁶⁵⁵ ⁶⁶⁰ ⁶⁶⁵ ⁶⁷⁰ ⁶⁷⁵ ⁶⁸⁰ ⁶⁸⁵ ⁶⁹⁰ ⁶⁹⁵ ⁷⁰⁰ ⁷⁰⁵ ⁷¹⁰ ⁷¹⁵ ⁷²⁰ ⁷²⁵ ⁷³⁰ ⁷³⁵ ⁷⁴⁰ ⁷⁴⁵ ⁷⁵⁰ ⁷⁵⁵ ⁷⁶⁰ ⁷⁶⁵ ⁷⁷⁰ ⁷⁷⁵ ⁷⁸⁰ ⁷⁸⁵ ⁷⁹⁰ ⁷⁹⁵ ⁸⁰⁰ ⁸⁰⁵ ⁸¹⁰ ⁸¹⁵ ⁸²⁰ ⁸²⁵ ⁸³⁰ ⁸³⁵ ⁸⁴⁰ ⁸⁴⁵ ⁸⁵⁰ ⁸⁵⁵ ⁸⁶⁰ ⁸⁶⁵ ⁸⁷⁰ ⁸⁷⁵ ⁸⁸⁰ ⁸⁸⁵ ⁸⁹⁰ ⁸⁹⁵ ⁹⁰⁰ ⁹⁰⁵ ⁹¹⁰ ⁹¹⁵ ⁹²⁰ ⁹²⁵ ⁹³⁰ ⁹³⁵ ⁹⁴⁰ ⁹⁴⁵ ⁹⁵⁰ ⁹⁵⁵ ⁹⁶⁰ ⁹⁶⁵ ⁹⁷⁰ ⁹⁷⁵ ⁹⁸⁰ ⁹⁸⁵ ⁹⁹⁰ ⁹⁹⁵ ¹⁰⁰⁰ ¹⁰⁰⁵ ¹⁰¹⁰ ¹⁰¹⁵ ¹⁰²⁰ ¹⁰²⁵ ¹⁰³⁰ ¹⁰³⁵ ¹⁰⁴⁰ ¹⁰⁴⁵ ¹⁰⁵⁰ ¹⁰⁵⁵ ¹⁰⁶⁰ ¹⁰⁶⁵ ¹⁰⁷⁰ ¹⁰⁷⁵ ¹⁰⁸⁰ ¹⁰⁸⁵ ¹⁰⁹⁰ ¹⁰⁹⁵ ¹¹⁰⁰ ¹¹⁰⁵ ¹¹¹⁰ ¹¹¹⁵ ¹¹²⁰ ¹¹²⁵ ¹¹³⁰ ¹¹³⁵ ¹¹⁴⁰ ¹¹⁴⁵ ¹¹⁵⁰ ¹¹⁵⁵ ¹¹⁶⁰ ¹¹⁶⁵ ¹¹⁷⁰ ¹¹⁷⁵ ¹¹⁸⁰ ¹¹⁸⁵ ¹¹⁹⁰ ¹¹⁹⁵ ¹²⁰⁰ ¹²⁰⁵ ¹²¹⁰ ¹²¹⁵ ¹²²⁰ ¹²²⁵ ¹²³⁰ ¹²³⁵ ¹²⁴⁰ ¹²⁴⁵ ¹²⁵⁰ ¹²⁵⁵ ¹²⁶⁰ ¹²⁶⁵ ¹²⁷⁰ ¹²⁷⁵ ¹²⁸⁰ ¹²⁸⁵ ¹²⁹⁰ ¹²⁹⁵ ¹³⁰⁰ ¹³⁰⁵ ¹³¹⁰ ¹³¹⁵ ¹³²⁰ ¹³²⁵ ¹³³⁰ ¹³³⁵ ¹³⁴⁰ ¹³⁴⁵ ¹³⁵⁰ ¹³⁵⁵ ¹³⁶⁰ ¹³⁶⁵ ¹³⁷⁰ ¹³⁷⁵ ¹³⁸⁰ ¹³⁸⁵ ¹³⁹⁰ ¹³⁹⁵ ¹⁴⁰⁰ ¹⁴⁰⁵ ¹⁴¹⁰ ¹⁴¹⁵ ¹⁴²⁰ ¹⁴²⁵ ¹⁴³⁰ ¹⁴³⁵ ¹⁴⁴⁰ ¹⁴⁴⁵ ¹⁴⁵⁰ ¹⁴⁵⁵ ¹⁴⁶⁰ ¹⁴⁶⁵ ¹⁴⁷⁰ ¹⁴⁷⁵ ¹⁴⁸⁰ ¹⁴⁸⁵ ¹⁴⁹⁰ ¹⁴⁹⁵ ¹⁵⁰⁰ ¹⁵⁰⁵ ¹⁵¹⁰ ¹⁵¹⁵ ¹⁵²⁰ ¹⁵²⁵ ¹⁵³⁰ ¹⁵³⁵ ¹⁵⁴⁰ ¹⁵⁴⁵ ¹⁵⁵⁰ ¹⁵⁵⁵ ¹⁵⁶⁰ ¹⁵⁶⁵ ¹⁵⁷⁰ ¹⁵⁷⁵ ¹⁵⁸⁰ ¹⁵⁸⁵ ¹⁵⁹⁰ ¹⁵⁹⁵ ¹⁶⁰⁰ ¹⁶⁰⁵ ¹⁶¹⁰ ¹⁶¹⁵ ¹⁶²⁰ ¹⁶²⁵ ¹⁶³⁰ ¹⁶³⁵ ¹⁶⁴⁰ ¹⁶⁴⁵ ¹⁶⁵⁰ ¹⁶⁵⁵ ¹⁶⁶⁰ ¹⁶⁶⁵ ¹⁶⁷⁰ ¹⁶⁷⁵ ¹⁶⁸⁰ ¹⁶⁸⁵ ¹⁶⁹⁰ ¹⁶⁹⁵ ¹⁷⁰⁰ ¹⁷⁰⁵ ¹⁷¹⁰ ¹⁷¹⁵ ¹⁷²⁰ ¹⁷²⁵ ¹⁷³⁰ ¹⁷³⁵ ¹⁷⁴⁰ ¹⁷⁴⁵ ¹⁷⁵⁰ ¹⁷⁵⁵ ¹⁷⁶⁰ ¹⁷⁶⁵ ¹⁷⁷⁰ ¹⁷⁷⁵ ¹⁷⁸⁰ ¹⁷⁸⁵ ¹⁷⁹⁰ ¹⁷⁹⁵ ¹⁸⁰⁰ ¹⁸⁰⁵ ¹⁸¹⁰ ¹⁸¹⁵ ¹⁸²⁰ ¹⁸²⁵ ¹⁸³⁰ ¹⁸³⁵ ¹⁸⁴⁰ ¹⁸⁴⁵ ¹⁸⁵⁰ ¹⁸⁵⁵ ¹⁸⁶⁰ ¹⁸⁶⁵ ¹⁸⁷⁰ ¹⁸⁷⁵ ¹⁸⁸⁰ ¹⁸⁸⁵ ¹⁸⁹⁰ ¹⁸⁹⁵ ¹⁹⁰⁰ ¹⁹⁰⁵ ¹⁹¹⁰ ¹⁹¹⁵ ¹⁹²⁰ ¹⁹²⁵ ¹⁹³⁰ ¹⁹³⁵ ¹⁹⁴⁰ ¹⁹⁴⁵ ¹⁹⁵⁰ ¹⁹⁵⁵ ¹⁹⁶⁰ ¹⁹⁶⁵ ¹⁹⁷⁰ ¹⁹⁷⁵ ¹⁹⁸⁰ ¹⁹⁸⁵ ¹⁹⁹⁰ ¹⁹⁹⁵ ²⁰⁰⁰ ²⁰⁰⁵ ²⁰¹⁰ ²⁰¹⁵ ²⁰²⁰ ²⁰²⁵ ²⁰³⁰ ²⁰³⁵ ²⁰⁴⁰ ²⁰⁴⁵ ²⁰⁵⁰ ²⁰⁵⁵ ²⁰⁶⁰ ²⁰⁶⁵ ²⁰⁷⁰ ²⁰⁷⁵ ²⁰⁸⁰ ²⁰⁸⁵ ²⁰⁹⁰ ²⁰⁹⁵ ²¹⁰⁰ ²¹⁰⁵ ²¹¹⁰ ²¹¹⁵ ²¹²⁰ ²¹²⁵ ²¹³⁰ ²¹³⁵ ²¹⁴⁰ ²¹⁴⁵ ²¹⁵⁰ ²¹⁵⁵ ²¹⁶⁰ ²¹⁶⁵ ²¹⁷⁰ ²¹⁷⁵ ²¹⁸⁰ ²¹⁸⁵ ²¹⁹⁰ ²¹⁹⁵ ²²⁰⁰ ²²⁰⁵ ²²¹⁰ ²²¹⁵ ²²²⁰ ²²²⁵ ²²³⁰ ²²³⁵ ²²⁴⁰ ²²⁴⁵ ²²⁵⁰ ²²⁵⁵ ²²⁶⁰ ²²⁶⁵ ²²⁷⁰ ²²⁷⁵ ²²⁸⁰ ²²⁸⁵ ²²⁹⁰ ²²⁹⁵ ²³⁰⁰ ²³⁰⁵ ²³¹⁰ ²³¹⁵ ²³²⁰ ²³²⁵ ²³³⁰ ²³³⁵ ²³⁴⁰ ²³⁴⁵ ²³⁵⁰ ²³⁵⁵ ²³⁶⁰ ²³⁶⁵ ²³⁷⁰ ²³⁷⁵ ²³⁸⁰ ²³⁸⁵ ²³⁹⁰ ²³⁹⁵ ²⁴⁰⁰ ²⁴⁰⁵ ²⁴¹⁰ ²⁴¹⁵ ²⁴²⁰ ²⁴²⁵ ²⁴³⁰ ²⁴³⁵ ²⁴⁴⁰ ²⁴⁴⁵ ²⁴⁵⁰ ²⁴⁵⁵ ²⁴⁶⁰ ²⁴⁶⁵ ²⁴⁷⁰ ²⁴⁷⁵ ²⁴⁸⁰ ²⁴⁸⁵ ²⁴⁹⁰ ²⁴⁹⁵ ²⁵⁰⁰ ²⁵⁰⁵ ²⁵¹⁰ ²⁵¹⁵ ²⁵²⁰ ²⁵²⁵ ²⁵³⁰ ²⁵³⁵ ²⁵⁴⁰ ²⁵⁴⁵ ²⁵⁵⁰ ²⁵⁵⁵ ²⁵⁶⁰ ²⁵⁶⁵ ²⁵⁷⁰ ²⁵⁷⁵ ²⁵⁸⁰ ²⁵⁸⁵ ²⁵⁹⁰ ²⁵⁹⁵ ²⁶⁰⁰ ²⁶⁰⁵ ²⁶¹⁰ ²⁶¹⁵ ²⁶²⁰ ²⁶²⁵ ²⁶³⁰ ²⁶³⁵ ²⁶⁴⁰ ²⁶⁴⁵ ²⁶⁵⁰ ²⁶⁵⁵ ²⁶⁶⁰ ²⁶⁶⁵ ²⁶⁷⁰ ²⁶⁷⁵ ²⁶⁸⁰ ²⁶⁸⁵ ²⁶⁹⁰ ²⁶⁹⁵ ²⁷⁰⁰ ²⁷⁰⁵ ²⁷¹⁰ ²⁷¹⁵ ²⁷²⁰ ²⁷²⁵ ²⁷³⁰ ²⁷³⁵ ²⁷⁴⁰ ²⁷⁴⁵ ²⁷⁵⁰ ²⁷⁵⁵ ²⁷⁶⁰ ²⁷⁶⁵ ²⁷⁷⁰ ²⁷⁷⁵ ²⁷⁸⁰ ²⁷⁸⁵ ²⁷⁹⁰ ²⁷⁹⁵ ²⁸⁰⁰ ²⁸⁰⁵ ²⁸¹⁰ ²⁸¹⁵ ²⁸²⁰ ²⁸²⁵ ²⁸³⁰ ²⁸³⁵ ²⁸⁴⁰ ²⁸⁴⁵ ²⁸⁵⁰ ²⁸⁵⁵ ²⁸⁶⁰ ²⁸⁶⁵ ²⁸⁷⁰ ²⁸⁷⁵ ²⁸⁸⁰ ²⁸⁸⁵ ²⁸⁹⁰ ²⁸⁹⁵ ²⁹⁰⁰ ²⁹⁰⁵ ²⁹¹⁰ ²⁹¹⁵ ²⁹²⁰ ²⁹²⁵ ²⁹³⁰ ²⁹³⁵ ²⁹⁴⁰ ²⁹⁴⁵ ²⁹⁵⁰ ²⁹⁵⁵ ²⁹⁶⁰ ²⁹⁶⁵ ²⁹⁷⁰ ²⁹⁷⁵ ²⁹⁸⁰ ²⁹⁸⁵ ²⁹⁹⁰ ²⁹⁹⁵ ³⁰⁰⁰ ³⁰⁰⁵ ³⁰¹⁰ ³⁰¹⁵ ³⁰²⁰ ³⁰²⁵ ³⁰³⁰ ³⁰³⁵ ³⁰⁴⁰ ³⁰⁴⁵ ³⁰⁵⁰ ³⁰⁵⁵ ³⁰⁶⁰ ³⁰⁶⁵ ³⁰⁷⁰ ³⁰⁷⁵ ³⁰⁸⁰ ³⁰⁸⁵ ³⁰⁹⁰ ³⁰⁹⁵ ³¹⁰⁰ ³¹⁰⁵ ³¹¹⁰ ³¹¹⁵ ³¹²⁰ ³¹²⁵ ³¹³⁰ ³¹³⁵ ³¹⁴⁰ ³¹⁴⁵ ³¹⁵⁰ ³¹⁵⁵ ³¹⁶⁰ ³¹⁶⁵ ³¹⁷⁰ ³¹⁷⁵ ³¹⁸⁰ ³¹⁸⁵ ³¹⁹⁰ ³¹⁹⁵ ³²⁰⁰ ³²⁰⁵ ³²¹⁰ ³²¹⁵ ³²²⁰ ³²²⁵ ³²³⁰ ³²³⁵ ³²⁴⁰ ³²⁴⁵ ³²⁵⁰ ³²⁵⁵ ³²⁶⁰ ³²⁶⁵ ³²⁷⁰ ³²⁷⁵ ³²⁸⁰ ³²⁸⁵ ³²⁹⁰ ³²⁹⁵ ³³⁰⁰ ³³⁰⁵ ³³¹⁰ ³³¹⁵ ³³²⁰ ³³²⁵ ³³³⁰ ³³³⁵ ³³⁴⁰ ³³⁴⁵ ³³⁵⁰ ³³⁵⁵ ³³⁶⁰ ³³⁶⁵ ³³⁷⁰ ³³⁷⁵ ³³⁸⁰ ³³⁸⁵ ³³⁹⁰ ³³⁹⁵ ³⁴⁰⁰ ³⁴⁰⁵ ³⁴¹⁰ ³⁴¹⁵ ³⁴²⁰ ³⁴²⁵ ³⁴³⁰ ³⁴³⁵ ³⁴⁴⁰ ³⁴⁴⁵ ³⁴⁵⁰ ³⁴⁵⁵ ³⁴⁶⁰ ³⁴⁶⁵ ³⁴⁷⁰ ³⁴⁷⁵ ³⁴⁸⁰ ³⁴⁸⁵ ³⁴⁹⁰ ³⁴⁹⁵ ³⁵⁰⁰ ³⁵⁰⁵ ³⁵¹⁰ ³⁵¹⁵ ³⁵²⁰ ³⁵²⁵ ³⁵³⁰ ³⁵³⁵ ³⁵⁴⁰ ³⁵⁴⁵ ³⁵⁵⁰ ³⁵⁵⁵ ³⁵⁶⁰ ³⁵⁶⁵ ³⁵⁷⁰ ³⁵⁷⁵ ³⁵⁸⁰ ³⁵⁸⁵ ³⁵⁹⁰ ³⁵⁹⁵ ³⁶⁰⁰ ³⁶⁰⁵ ³⁶¹⁰ ³⁶¹⁵ ³⁶²⁰ ³⁶²⁵ ³⁶³⁰ ³⁶³⁵ ³⁶⁴⁰ ³⁶⁴⁵ ³⁶⁵⁰ ³⁶⁵⁵ ³⁶⁶⁰ ³⁶⁶⁵ ³⁶⁷⁰ ³⁶⁷⁵ ³⁶⁸⁰ ³⁶⁸⁵ ³⁶⁹⁰ ³⁶⁹⁵ ³⁷⁰⁰ ³⁷⁰⁵ ³⁷¹⁰ ³⁷¹⁵ ³⁷²⁰ ³⁷²⁵ ³⁷³⁰ ³⁷³⁵ ³⁷⁴⁰ ³⁷⁴⁵ ³⁷⁵⁰ ³⁷⁵⁵ ³⁷⁶⁰ ³⁷⁶⁵ ³⁷⁷⁰ ³⁷⁷⁵ ³⁷⁸⁰ ³⁷⁸⁵ ³⁷⁹⁰ ³⁷⁹⁵ ³⁸⁰⁰ ³⁸⁰⁵ ³⁸¹⁰ ³⁸¹⁵ ³⁸²⁰ ³⁸²⁵ ³⁸³⁰ ³⁸³⁵ ³⁸⁴⁰ ³⁸⁴⁵ ³⁸⁵⁰ ³⁸⁵⁵ ³⁸⁶⁰ ³⁸⁶⁵ ³⁸⁷⁰ ³⁸⁷⁵ ³⁸⁸⁰ ³⁸⁸⁵ ³⁸⁹⁰ ³⁸⁹⁵ ³⁹⁰⁰ ³⁹⁰⁵ ³⁹¹⁰ ³⁹¹⁵ ³⁹²⁰ ³⁹²⁵ ³⁹³⁰ ³⁹³⁵ ³⁹⁴⁰ ³⁹⁴⁵ ³⁹⁵⁰ ³⁹⁵⁵ ³⁹⁶⁰ ³⁹⁶⁵ ³⁹⁷⁰ ³⁹⁷⁵ ³⁹⁸⁰ ³⁹⁸⁵ ³⁹⁹⁰ ³⁹⁹⁵ ⁴⁰⁰⁰ ⁴⁰⁰⁵ ⁴⁰¹⁰ ⁴⁰¹⁵ ⁴⁰²⁰ ⁴⁰²⁵ ⁴⁰³⁰ ⁴⁰³⁵ ⁴⁰⁴⁰ ⁴⁰⁴⁵ ⁴⁰⁵⁰ ⁴⁰⁵⁵ ⁴⁰⁶⁰ ⁴⁰⁶⁵ ⁴⁰⁷⁰ ⁴⁰⁷⁵ ⁴⁰⁸⁰ ⁴⁰⁸⁵ ⁴⁰⁹⁰ ⁴⁰⁹⁵ ⁴¹⁰⁰ ⁴¹⁰⁵ ⁴¹¹⁰ ⁴¹¹⁵ ⁴¹²⁰ ⁴¹²⁵ ⁴¹³⁰ ⁴¹³⁵ ⁴¹⁴⁰ ⁴¹⁴⁵ ⁴¹⁵⁰ ⁴¹⁵⁵ ⁴¹⁶⁰ ⁴¹⁶⁵ ⁴¹⁷⁰ ⁴¹⁷⁵ ⁴¹⁸⁰ ⁴¹⁸⁵ ⁴¹⁹⁰ ⁴¹⁹⁵ ⁴²⁰⁰ ⁴²⁰⁵ ⁴²¹⁰ ⁴²¹⁵ ⁴²²⁰ ⁴²²⁵ ⁴²³⁰ ⁴²³⁵ ⁴²⁴⁰ ⁴²⁴⁵ ⁴²⁵⁰ ⁴²⁵⁵ ⁴²⁶⁰ ⁴²⁶⁵ ⁴²⁷⁰ ⁴²⁷⁵ ⁴²⁸⁰ ⁴²⁸⁵ ⁴²⁹⁰ ⁴²⁹⁵ ⁴³⁰⁰ ⁴³⁰⁵ ⁴³¹⁰ ⁴³¹⁵ ⁴³²⁰ ⁴³²⁵ ⁴³³⁰ ⁴³³⁵ ⁴³⁴⁰ ⁴³⁴⁵ ⁴³⁵⁰ ⁴³⁵⁵ ⁴³⁶⁰ ⁴³⁶⁵ ⁴³⁷⁰ ⁴³⁷⁵ ⁴³⁸⁰ ⁴³⁸⁵ ⁴³⁹⁰ ⁴³⁹⁵ ⁴⁴⁰⁰ ⁴⁴⁰⁵ ⁴⁴¹⁰ ⁴⁴¹⁵ ⁴⁴²⁰ ⁴⁴²⁵ ⁴⁴³⁰ ⁴⁴³⁵ ⁴⁴⁴⁰ ⁴⁴⁴⁵ ⁴⁴⁵⁰ ⁴⁴⁵⁵ ⁴⁴⁶⁰ ⁴⁴⁶⁵ ⁴⁴⁷⁰ ⁴⁴⁷⁵ ⁴⁴⁸⁰ ⁴⁴⁸⁵ ⁴⁴⁹⁰ ⁴⁴⁹⁵ ⁴⁵⁰⁰ ⁴⁵⁰⁵ ⁴⁵¹⁰ ⁴⁵¹⁵ ⁴⁵²⁰ ⁴⁵²⁵ ⁴⁵³⁰ ⁴⁵³⁵ ⁴⁵⁴⁰ ⁴⁵⁴⁵ ⁴⁵⁵⁰ ⁴⁵⁵⁵ ⁴⁵⁶⁰ ⁴⁵⁶⁵ ⁴⁵⁷⁰ ⁴⁵⁷⁵ ⁴⁵⁸⁰ ⁴⁵⁸⁵ ⁴⁵⁹⁰ ⁴⁵⁹⁵ ⁴⁶⁰⁰ ⁴⁶⁰⁵ ⁴⁶¹⁰ ⁴⁶¹⁵ ⁴⁶²⁰ ⁴⁶²⁵ ⁴⁶³⁰ ⁴⁶³⁵ ⁴⁶⁴⁰ ⁴⁶⁴⁵ ⁴⁶⁵⁰ ⁴⁶⁵⁵ ⁴⁶⁶⁰ ⁴⁶⁶⁵ ⁴⁶⁷⁰ ⁴⁶⁷⁵ ⁴⁶⁸⁰ ⁴⁶⁸⁵ ⁴⁶⁹⁰ ⁴⁶⁹⁵ ⁴⁷⁰⁰ ⁴⁷⁰⁵ ⁴⁷¹⁰ ⁴⁷¹⁵ ⁴⁷²⁰ ⁴⁷²⁵ ⁴⁷³⁰ ⁴⁷³⁵ ⁴⁷⁴⁰ ⁴⁷⁴⁵ ⁴⁷⁵⁰ ⁴⁷⁵⁵ ⁴⁷⁶⁰ ⁴⁷⁶⁵ ⁴⁷⁷⁰ ⁴⁷⁷⁵ ⁴⁷⁸⁰ ⁴⁷⁸⁵ ⁴⁷⁹⁰ ⁴⁷⁹⁵ ⁴⁸⁰⁰ ⁴⁸⁰⁵ ⁴⁸¹⁰ ⁴⁸¹⁵ ⁴⁸²⁰ ⁴⁸²⁵ ⁴⁸³⁰ ⁴⁸³⁵ ⁴⁸⁴⁰ ⁴⁸⁴⁵ ⁴⁸⁵⁰ ⁴⁸⁵⁵ ⁴⁸⁶⁰ ⁴⁸⁶⁵ ⁴⁸⁷⁰ ⁴⁸⁷⁵ ⁴⁸⁸⁰ ⁴⁸⁸⁵ ⁴⁸⁹⁰ ⁴⁸⁹⁵ ⁴⁹⁰⁰ ⁴⁹⁰⁵ ⁴⁹¹⁰ ⁴⁹¹⁵ ⁴⁹²⁰ ⁴⁹²⁵ ⁴⁹³⁰ ⁴⁹³⁵ ⁴⁹⁴⁰ ⁴⁹⁴⁵ ⁴⁹⁵⁰ ⁴⁹⁵⁵ ⁴⁹⁶⁰ ⁴⁹⁶⁵ ⁴⁹⁷⁰ ⁴⁹⁷⁵ ⁴⁹⁸⁰ ⁴⁹⁸⁵ ⁴⁹⁹⁰ ⁴⁹⁹⁵ ⁵⁰⁰⁰ ⁵⁰⁰⁵ ⁵⁰¹⁰ ⁵⁰¹⁵ ⁵⁰²⁰ ⁵⁰²⁵ ⁵⁰³⁰ ⁵⁰³⁵ ⁵⁰⁴⁰ ⁵⁰⁴⁵ ⁵⁰⁵⁰ ⁵⁰⁵⁵ ⁵⁰⁶⁰ ⁵⁰⁶⁵ ⁵⁰⁷⁰ ⁵⁰⁷⁵ ⁵⁰⁸⁰ ⁵⁰⁸⁵ ⁵⁰⁹⁰ ⁵⁰⁹⁵ ⁵¹⁰⁰ ⁵¹⁰⁵ ⁵¹¹⁰ ⁵¹¹⁵ ⁵¹²⁰ ⁵¹²⁵ ⁵¹³⁰ ⁵¹³⁵ ⁵¹⁴⁰ ⁵¹⁴⁵ ⁵¹⁵⁰ ⁵¹⁵⁵ ⁵¹⁶⁰ ⁵¹⁶⁵ ⁵¹⁷⁰ ⁵¹⁷⁵ ⁵¹⁸⁰ ⁵¹⁸⁵ ⁵¹⁹⁰ ⁵¹⁹⁵ ⁵²⁰⁰ ⁵²⁰⁵ ⁵²¹⁰ ⁵²¹⁵ ⁵²²⁰ ⁵²²⁵ ⁵²³⁰ ⁵²³⁵ ⁵²⁴⁰ ⁵²⁴⁵ ⁵²⁵⁰ ⁵²⁵⁵ ⁵²⁶⁰ ⁵²⁶⁵ ⁵²⁷⁰ ⁵²⁷⁵ ⁵²⁸⁰ ⁵²⁸⁵ ⁵²⁹⁰ ⁵²⁹⁵ ⁵³⁰⁰ ⁵³⁰⁵ ⁵³¹⁰ ⁵³¹⁵ ⁵³²⁰ ⁵³²⁵ ⁵³³⁰ ⁵³³⁵ ⁵³⁴⁰ ⁵³⁴⁵ ⁵³⁵⁰ ⁵³⁵⁵ ⁵³⁶⁰ ⁵³⁶⁵ ⁵³⁷⁰ ⁵³⁷⁵ ⁵³⁸⁰ ⁵³⁸⁵ ⁵³⁹⁰ ⁵³⁹⁵ ⁵⁴⁰⁰ ⁵⁴⁰⁵ ⁵⁴¹⁰ ⁵⁴¹⁵ ⁵⁴²⁰ ⁵⁴²⁵ ⁵⁴³⁰ ⁵⁴³⁵ ⁵⁴⁴⁰ ⁵⁴⁴⁵ ⁵⁴⁵⁰ ⁵⁴⁵⁵ ⁵⁴⁶⁰ ⁵⁴⁶⁵ ⁵⁴⁷⁰ ⁵⁴⁷⁵ ⁵⁴⁸⁰ ⁵⁴⁸⁵ ⁵⁴⁹⁰ ⁵⁴⁹⁵ ⁵⁵⁰⁰ ⁵⁵⁰⁵ ⁵⁵¹⁰ ⁵⁵¹⁵ ⁵⁵²⁰ ⁵⁵²⁵ ⁵⁵³⁰ ⁵⁵³⁵ ⁵⁵⁴⁰ ⁵⁵⁴⁵ ⁵⁵⁵⁰ ⁵⁵⁵⁵ ⁵⁵⁶⁰ ⁵⁵⁶⁵ ⁵⁵⁷⁰ ⁵⁵⁷⁵ ⁵⁵⁸⁰ ⁵⁵⁸⁵ ⁵⁵⁹⁰ ⁵⁵⁹⁵ ⁵⁶⁰⁰ ⁵⁶⁰⁵ ⁵⁶¹⁰ ⁵⁶¹⁵ ⁵⁶²⁰ ⁵⁶²⁵ ⁵⁶³⁰ ⁵⁶³⁵ ⁵⁶⁴⁰ ⁵⁶⁴⁵ ⁵⁶⁵⁰ ⁵⁶⁵⁵ ⁵⁶⁶⁰ ⁵⁶⁶⁵ ⁵⁶⁷⁰ ⁵⁶⁷⁵ ⁵⁶⁸⁰ ⁵⁶⁸⁵ ⁵⁶⁹⁰ ⁵⁶⁹⁵ ⁵⁷⁰⁰ ⁵⁷⁰⁵ ⁵⁷¹⁰ ⁵⁷¹⁵ ⁵⁷²⁰ ⁵⁷²⁵ ⁵⁷³⁰ ⁵⁷³⁵ ⁵⁷⁴⁰ ⁵⁷⁴⁵ ⁵⁷⁵⁰ ⁵⁷⁵⁵ ⁵⁷⁶⁰ ⁵⁷⁶⁵ ⁵⁷⁷⁰ ⁵⁷⁷⁵ ⁵⁷⁸⁰ ⁵⁷⁸⁵ ⁵⁷⁹⁰ ⁵⁷⁹⁵ <sup

Method A

- 5 a) 2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy-3-(S)-(4-fluorophenyl)-4-propargylmorpholine

Propargyl bromide (1.9ml) was added to a stirred mixture of the compound of Description 5 (5g) and potassium carbonate (4.76g) in dry dimethylformamide at 23°C. After 15 min the reaction mixture was 10 diluted with water (250ml) and extracted with ethyl acetate (3 x 100ml). The combined organic phases were washed with brine (1 x 100ml) then dried (K_2CO_3) and concentrated to leave an oil. This was purified by chromatography on silica using ethyl acetate in hexane (1:9 then 1:4) as eluent to afford the title compound as an oil. 1H NMR (250MHz, $CDCl_3$) δ 15 1.50 (3H, d, $J=6.6Hz$), 2.21 (1H, s), 2.84 (1H, d, $J=11.1Hz$), 2.97 (1H, td, $J=3.2, 11.7Hz$), 3.26 (2H, d, $J=1.8Hz$), 3.62 (1H, d, $J=2.2Hz$), 3.71 (1H, dd, $J=2.3, 11.1Hz$), 4.33 (2H, m), 4.89 (1H, q, $J=6.6Hz$), 7.03 (2H, t, $J=8.6Hz$), 7.18 (2H, s), 7.38 (2H, br s), 7.63 (1H, s). MS (CI^+) m/z 476 (MH, 100%).

- 20 b) 2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-4-(4-dimethylamino-4-oxo-but-2-ynyl)-3-(S)-(4-fluorophenyl)morpholine

A mixture of N,N-dimethylcarbamoyl chloride (0.195ml), cuprous iodide (2mg), bis(triphenylphosphine)palladium (II) chloride (2mg), triphenylphosphine (3mg) and the compound described in (a) above (1g) in 25 triethylamine (4ml) was heated at 90°C for 5h in an inert atmosphere. The mixture was cooled to 23°C and methanol (1ml) was added and the solvent was removed *in vacuo*. The residue was partitioned between water and ethyl acetate and the layers were separated. The aqueous phase was extracted with ethyl acetate (2 x 20ml). The combined organic 30 phases were washed with water, brine, dried ($MgSO_4$) and concentrated to leave an oil. The residue was purified by chromatography on silica using

ethyl acetate in hexane (1:1) then ethyl acetate as eluant to provide the title compound as an oil. ^1H NMR (250MHz, CDCl_3) δ 1.49 (3H, d, $J=6.6\text{Hz}$), 2.84-3.06 (2H, m), 3.00 (3H, s), 3.17 (3H, s), 3.44 (2H, s), 3.64 (1H, br s), 3.73 (1H, dd, $J=2.0, 11.1\text{Hz}$), 4.33 (2H, m), 4.88 (1H, q, $J=6.6\text{Hz}$), 7.03 (2H, t, $J=8.7\text{Hz}$), 7.17 (2H, s), 7.38 (2H, br s), 7.63 (1H, s). MS (Cl^+) m/z 547 (MH, 100%).

10 c) 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenyl)ethoxy)-4-(5-N,N-dimethylcarboxamido-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine

A mixture of the compound described in (b) above (1.1g) and sodium azide (0.65g) in dimethylsulphoxide (7.5ml) was heated at 70°C for 17h. The mixture was cooled to 23°C and excess dimethylsulphoxide was removed by distillation *in vacuo*. The residue was partitioned between 15 brine and ethyl acetate. The layers were separated and the organic layer was washed with brine (2 x 20ml) then dried (MgSO_4) and concentrated to leave an oil. This was purified by chromatography on silica using ethyl acetate in hexane (1:2 then 1:1) and then ethyl acetate as eluent to provide the title compound as a pale yellow foam. ^1H NMR (360MHz, CDCl_3) δ 1.47 (3H, d, $J=6.6\text{Hz}$), 2.64 (1H, m), 2.90 (1H, d, $J=11.6\text{Hz}$), 3.09 (3H, s), 3.34 (3H, s), 3.65 (3H, m), 3.92 (1H, d, $J=15.5\text{Hz}$), 4.27 (1H, td, $J=2.1, 9.5\text{Hz}$), 4.35 (1H, d, $J=2.6\text{Hz}$), 4.89 (1H, q, $J=6.6\text{Hz}$), 7.01 (2H, t, $J=8.7\text{Hz}$), 7.16 (2H, s), 7.39 (2H, br s), 7.64 (1H, s). m/z 590 (MH, 100%).

25 d) 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(dimethylaminomethyl)-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine

Lithium aluminium hydride (0.47ml, 1M in tetrahydrofuran) was added dropwise to a solution of the compound described in (c) above 30 (0.11g) in dry tetrahydrofuran (1ml) under an inert atmosphere at 23°C . After 30 min sodium hydroxide (10 drops, 1M) was added followed by

water (5 drops). Ethyl acetate (50ml) was then added and the resulting mixture was filtered through a pad of Hyflo™. The filtrate was concentrated *in vacuo* and the residue was purified by chromatography on silica using ethyl acetate in methanol (9:1 then 4:1) as eluant to provide
5 the title compound as a foam.¹H NMR (360MHz, CDCl₃) δ 1.44 (3H, d, J=6.6Hz), 2.25 (6H, s), 2.57 (1H, td, J=3.4, 8.55Hz), 2.90 (1H, d, J=11.7Hz), 3.25 (1H, d, J=14.0Hz), 3.43 (1H, d, J=13.6Hz), 3.45 (1H, d, J=2.2Hz), 3.53 (1H, d, J=13.6Hz), 3.61 (1H, d, J=11.2Hz), 3.78 (1H, d, J=14.0Hz), 4.22 (1H, t, J=9.3Hz), 4.32 (1H, d, J=2.2Hz), 4.86 (1H, q, J=6.6Hz), 7.06 (2H, t, J=8.7Hz), 7.16 (2H, s), 7.48 (2H, br s), 7.63 (1H, s).
10 m/z 576 (MH).

Method B

2-(R)-1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy-3-(S)-(4-fluorophenyl)-4-(4-chlorobut-2-ynyl)morpholine

a) A solution of the product of Description 5 (free base, 5g) in N,N-dimethylformamide (20ml) was slowly added to a heated (50°C) solution of 1,4-dichlorbut-2-yne (2.2ml) and potassium carbonate (4.8g) in N,N-dimethylformamide (20ml). The solution was heated for a further 5h at
15 50°C and then the solvent removed *in vacuo*. To the residue was added water (400ml) and the product extracted into ethyl acetate (3 x 150ml). The combined organic phase washed with water, saturated brine and dried (MgSO₄). The solvent was removed *in vacuo* and the residue chromatographed on silica gel (eluting with 10% ethyl acetate in
20 petroleum ether bp 60-80°C) to give the title compound. ¹H NMR (250MHz, CDCl₃) δ 1.41 (3H, d, J=6.6Hz), 2.80 (1H, app. t, J=10.8Hz), 2.87 (1H, td, J=3.5Hz, 11.7Hz), 3.22 (2H, t, J=1.9Hz), 3.52 (1H, d, J=2.8Hz), 3.68 (1H, d, J=1.4Hz, 11.1Hz), 4.00 (2H, t, J=1.9Hz), 4.22-4.32 (2H, m), 4.81 (1H, q, J=6.6Hz), 6.96 (2H, t, J=8.7Hz), 7.10 (2H, s), 7.31 (2H, br s),
25 7.56 (1H, s). m/z (CI⁺) 524 (M+H, 100%).

30

b) N-(4-Azidobut-2-ynyl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine

5 To a solution of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(4-chlorobut-2-ynyl)morpholine (4g) in dimethyl sulphoxide (17ml) was added sodium azide (0.562g). The solution was stirred for 20h and aqueous ammonium chloride and ethyl acetate were added. The organic phase was washed with water (2 times),
10 saturated brine and dried (MgSO_4). The solvent was removed *in vacuo* and the residue chromatographed on silica gel (eluting with 20% ethyl acetate in petroleum ether bp 60-80°C) to give the title compound. ^1H NMR (360MHz, CDCl_3) δ 1.48 (3H, s, $J=6.6\text{Hz}$), 2.87 (1H, app t, $J=10.2\text{Hz}$), 2.98 (1H, td, $J=3.6, 11.7\text{Hz}$), 3.35 (2H, t, $J=1.9\text{Hz}$), 3.61 (1H, d, $J=2.8\text{Hz}$), 3.72 (1H, dq, $J=1.4\text{Hz}, 10.0\text{Hz}$), 3.92 (2H, t, $J=1.9\text{Hz}$), 4.30-4.40 (2H, m), 4.89(1H, q, $J=6.6\text{Hz}$), 7.03 (2H, t, $J=8.7\text{Hz}$), 7.17 (2H, s), 7.27 (2H, br s), 7.63 (1H, s).

c) 2-(R)-(1-(R)-3,5-Bis(trifluoromethyl)phenyl)ethoxy-4-(5-(dimethylaminomethyl)-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine

Dimethylamine (approximately 10ml) was condensed at -80°C in a pressure tube and to this was added a solution of N-(4-azidobut-2-ynyl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine (3.2g) in dioxan (15ml). The tube was sealed and the solution was heated at 90°C for 16h. The solution was evaporated to dryness and the residue chromatographed on silica gel (eluting with 5% methanol in dichloromethane containing 0.25% ammonia (SG. 0.88)) and the fractions containing the desired product were evaporated *in vacuo* to give the title compound. To a solution of this residue in diethyl ether was added 1M-HCl in methanol. The solution was evaporated to dryness and

redissolved in diethyl ether to give crystals of the title compound hydrochloride salt m.p. 194-198°C, $[\alpha]^{25}_D + 65.0^\circ$ ($c=0.5$, H₂O). The crystals were found to be stable for at least five days at 40°C; at 40°C/75% relative humidity; at 80°C; and at 2000LUX.

5

DESCRIPTION 10

3-(S)-(4-Fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl)ethoxy)-4-(5-pyrrolidinomethyl-1,2,3-triazol-4-yl)methylmorpholine

The title compound was prepared from the compound of Description 8 according to the method of Description 9, Method B, via the corresponding N-(4-azidobut-2-ynyl)morpholine and pyrrolidine. ¹H NMR (360MHz, CDCl₃) δ 1.40 (3H, d, J=6.6Hz), 1.81 (4H, br s), 2.53-2.61 (5H, m), 2.89 (1H, d, J=11.7Hz), 3.27 (1H, d, J=14.0Hz), 3.45 (1H, d, J=2.8Hz), 2.59-3.63 (1H, m), 3.63 (1H, d, J=13.7Hz), 3.73 (1H, d, J=13.7Hz), 3.83 (1H, d, J=14.0Hz), 4.21 (1H, dt, J=11.6, 2.1Hz), 4.32 (1H, d, J=2.8Hz), 4.76 (1H, q, J=6.5Hz), 6.37 (1H, d, J=9.1Hz), 6.80 (1H, s), 7.05-7.10 (3H, m), 7.46 (2H, br s). MS (CI⁺) 552 (M+1, 100%).

DESCRIPTION 11

20 3-(S)-(4-Fluorophenyl)-2-(R)-(1-(R)-(3-methylthio-5-(trifluoromethyl)phenyl)ethoxy)-4-(5-pyrrolidinomethyl-1,2,3-triazol-4-yl)methylmorpholine

The compound of Description 10 (0.5mmol) was heated to 120°C with sodium thiomethoxide (2.5mmol) in anhydrous DMF (10ml) for 25 between 2-5 hours. The cooled solution was diluted with water (150ml), extracted with ethyl acetate (4 x 40ml), dried (MgSO₄) and concentrated *in vacuo* to a crude oil which was purified by flash silica gel chromatography in 5-10% methanol/dichloromethane to yield the title compound as a foam (620mg, 81%). ¹H NMR (360MHz, CDCl₃) δ 1.40 (3H, d, J=6.6Hz), 1.79 (4H, br s), 2.36 (3H, s), 2.5-2.6 (5H, m), 2.87 (1H, d, J=11.7Hz), 3.23 (1H, d, J=13.9Hz), 3.43 (1H, d, J=2.8Hz), 3.57-3.64 (2H,

m), 3.71 (1H, d, J=13.7Hz), 3.78 (1H, d, J=14.0Hz), 4.21 (1H, m), 4.33 (1H, d, J=2.8Hz), 4.74 (1H, q, J=6.5Hz), 6.71 (2H, s), 7.06 (2H, t, J=8.7Hz), 7.19 (1H, s), 7.47 (2H, br s); MS (ES⁺) m/z 580 (M+1, 100%).

5

EXAMPLE 1

2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(5-(N,N-dimethylamino(N-oxide)methyl)-1,2,3-triazol-4-yl)methylmorpholine

- To a heated (60°C) solution of 2-(R)-(1-(R)-(3,5-
10 bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(5-(N,N-
dimethylaminomethyl)-1,2,3-triazol-4-yl)methylmorpholine (Description 9)
(0.245g, 0.442mmol) dissolved in soya bean oil (6ml) was added a 30%
solution of aqueous hydrogen peroxide (0.2ml) in portions over 4h. The
solution was then cooled to room temperature for 16 hours and the
15 resulting suspension applied to a column containing silica and the
products eluted with a gradient between dichloromethane and a mixture
of dichloromethane:methanol:aqueous ammonia solution (200:50:1). This
crude product was recrystallised from aqueous ethanol to give the title
compound mp 139-140°C. m/z (Cl⁺) 592 (M+H).
20 Analysis Calcd. for C₂₆H₂₈F₇N₅O₃. 0.8H₂O: C, 51.54; H, 4.92; N, 11.56;
Found: C, 51.52; H, 4.71; N, 11.21%
¹H NMR (360MHz, CH₃OH-d₄) δ 1.47 (3H, d, J=6.58Hz), 2.54 (1H, td), 2.78
(1H, d, J=11.95Hz), 3.10 (3H, s), 3.15 (3H, s), 3.35 (1H, AB d, J=14.49Hz),
3.50 (1H, d), 3.63 (1H, br d, J=11.53Hz), 3.82 (1H, AB d, J=14.5Hz), 4.23
25 (1H, td), 4.29 (1H, AB d, J=13.55Hz), 4.36 (1H, d, J=2.69Hz), 4.49 (1H, AB
d, J=13.43Hz), 4.96 (1H, q, J=6.48Hz), 7.08 (2H, t, J=8.7Hz), 7.35 (2H, s),
7.56 (2H, br t), 7.71 (1H, s).

EXAMPLE 2

2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(5-(N,N-dimethylaminomethyl)-1,2,3-triazol-4-yl) methylmorpholine 1-oxide

5 To a solution of 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(5-(N,N-dimethylaminomethyl)-1,2,3-triazol-4-yl)methylmorpholine (Description 9) (0.245g, 0.442mmol) dissolved in dichloromethane (3.6ml) and acetic acid (1.81ml) was added a solution of 30% aqueous hydrogen peroxide (0.368ml). The solution was
10 stirred at room temperature for 16 hours and was then chromatographed on silica gel eluting with a gradient between chloroform and a mixture of chloroform: methanol:acetic acid:water (800:200:30:3) and then chromatographed on silica gel eluting with a gradient between dichloromethane and a mixture of dichloromethane:methanol:aqueous
15 ammonia solution (200:50:1), to give, after evaporation and washing with hexane, the title compound mp 132-134°C. m/z (Cl⁺) 592 (M+H).
Analysis Calcd. for C₂₈H₂₈F₇N₅O₃. 1.3H₂O: C, 50.78; H, 5.02; N, 11.39;
Found: C, 50.67; H, 5.05; N, 11.15%
¹H NMR (360MHz, CH₃OH-d₄) δ 1.59 (3H, d, J=6.59Hz), 2.90 (1H, d,
20 12.95Hz), 3.78 (2H, m), 3.90 (1H, AB d, J=13.41Hz), 4.00 (1H, AB d,
J=13.59Hz), 4.06 (1H, AB d, J=13.21Hz), 4.50 (1H, AB d, J=13.26Hz), 4.71
(1H, d, J=3.56Hz), 4.89 (1H, d, J=3.61Hz), 5.00 (1H, q, J=6.47Hz), 7.15
(2H, t, J=8.28Hz), 7.62 (2H, s), 8.0 (2H, vbr s), 7.76 (1H, s).

25

EXAMPLE 3

2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(5-(N,N-dimethylamino(N-oxide)methyl)-1,2,3-triazol-4-yl)methylmorpholine N-oxide

From the chromatographic separation described in Example 1 was
30 isolated the title compound m/z (Cl⁺) 608 (M+H).

EXAMPLE 4

3-(S)-(4-Fluorophenyl)-2-(R)-(1-(R)-(3-methylthio-5-(trifluoromethyl)phenyl)ethoxy)-4-(5-pyrrolidinomethyl-1,2,3-triazol-4-yl)methylmorpholine N-oxide

- 5 The thioether of Description 11 (557mg, 0.96mmol) was dissolved in chloroform (10ml) and cooled to -24°C. *m*-Chloroperoxybenzoic acid (80-85%, 207 mg, 0.96mmol) was added quickly in portions and the reaction mixture stirred at this temperature for 1 hour before warming to room temperature. The resulting solution was diluted with chloroform (20ml),
10 washed with sodium bicarbonate solution (30ml, 0.5M), dried (MgSO_4) and concentrated *in vacuo*. The crude concentrate was purified by flash silica gel chromatography eluting with dichloromethane/methanol/concentrated aqueous ammonia (91:8:1 to 86:12:2) to yield in order, recovered starting material (143mg, 26%); the title compound (morpholine N-oxide) (121mg, 21%); and the bis(N-oxide) (Example 5) (153mg, 26%), all as foams.
15 Analysis Calcd. for $\text{C}_{23}\text{H}_{33}\text{F}_4\text{N}_5\text{O}_8\text{S} \cdot 2\text{H}_2\text{O}$: C, 53.24; H, 5.90; N, 11.09;
Found: C, 53.24; H, 5.74; N, 10.76%
 ^1H NMR (360MHz, CDCl_3) δ 1.41 (3H, d, $J=6.5\text{Hz}$), 1.90 (4H, br s), 2.28 (3H, s), 2.70-2.80 (2H, m), 2.84 (1H, d, $J=12.6\text{Hz}$), 2.90-3.00 (2H, m), 3.59 (1H, d, $J=12.0\text{Hz}$), 3.80 (1H, d, $J=13.0\text{Hz}$), 3.80-3.88 (1H, m), 3.90 (1H, d, $J=13.1\text{Hz}$), 3.98 (1H, d, $J=13.0\text{Hz}$), 4.61-4.71 (3H, m), 4.87 (1H, d, $J=2.6\text{Hz}$), 4.89 (1H, m), 6.87 (2H, s), 7.00 (2H, br t, $J=8.1\text{Hz}$), 7.16 (1H, s), 7.6-8.2 (~2H, vbr s); MS (ES⁺) 596 (M+1, 100%); HPLC 96-98% pure.

25

EXAMPLE 5


3-(S)-(4-Fluorophenyl)-2-(R)-(1-(R)-(3-methylthio-5-(trifluoromethyl)phenyl)ethoxy)-4-(5-pyrrolidino(N-oxide)methyl-1,2,3-triazol-4-yl)methylmorpholine N-oxide

- From the chromatography described in Example 4. ^1H NMR
30 (360MHz, CDCl_3) δ 1.45 (3H, d, $J=6.6\text{Hz}$), 1.90-2.40 (4H, br m), 2.28 (3H, s), 3.24 (1H, d, $J=12.9\text{Hz}$), 3.35 (1H, m), 3.56-3.85 (5H, br m), 4.08 (1H, d,

J=13.0Hz), 4.50 (1H, d, J=13.1Hz), 4.56-4.71 (3H, m), 4.83 (1H, d, J=13.1Hz), 5.04 (1H, d, J=3.4Hz), 5.13 (1H, d, J=13.0Hz), 6.89 (2H, s), 6.99 (2H, br t), 7.16 (1H, s), 7.6-8.2 (~2H, vbr s); MS (ES⁺) 612 (M+1, 100%).

CLAIMS:

1. A compound of the formula (I):



5

(I)

wherein

- R¹ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, CF₃, OCF₃, NO₂, CN, SR^a, SOR^a, SO₂R^a, CO₂R^a, CONR^aR^b, C₂₋₆alkenyl, C₂₋₆alkynyl or C₁₋₄alkyl
10 substituted by C₁₋₄alkoxy, wherein R^a and R^b each independently represent hydrogen or C₁₋₄alkyl;
- R² is hydrogen, halogen, C₁₋₆alkyl, CF₃, OCF₃ or C₁₋₆alkoxy substituted by C₁₋₄alkoxy;
- R³ is hydrogen, halogen, CF₃ or OCF₃;
- 15 R⁴ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, CF₃, NO₂, CN, SR^a, SOR^a, SO₂R^a, CO₂R^a, CONR^aR^b, C₂₋₆alkenyl, C₂₋₆alkynyl or C₁₋₄alkyl substituted by C₁₋₄alkoxy, wherein R^a and R^b are as previously defined;
- R⁵ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy substituted by C₁₋₄alkoxy or CF₃;
- 20 R⁶ is hydrogen, C₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, or C₂₋₄alkyl substituted by C₁₋₄alkoxy or hydroxy;

R⁷ is hydrogen, C₁₋₄alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, or C₂₋₄alkyl substituted by one or two substituents selected from C₁₋₄alkoxy, hydroxy or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S;

- 5 or R⁶ and R⁷, together with the nitrogen atom to which they are attached, form a saturated or partially saturated heterocyclic ring of 4 to 7 ring atoms, which ring may optionally contain in the ring one oxygen or sulphur atom or a group selected from NR⁸, S(O) or S(O)₂ and which ring may be optionally substituted by one or two groups selected from hydroxy, 10 C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, oxo, COR^a or CO₂R^a where R^a is as previously defined;
- 15 or R⁶ and R⁷ together with the nitrogen atom to which they are attached, form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms;
- 15 or Z, R⁶ and the nitrogen atom to which they are attached form a heteroaliphatic ring of 4 to 7 ring atoms which may optionally contain an oxygen ring atom;
- 15 R⁸ is hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C₁₋₄alkoxyC₁₋₄alkyl;
- 15 R^{9a} and R^{9b} are each independently hydrogen or C₁₋₄alkyl, or R^{9a} and 20 R^{9b} are joined so, together with the carbon atoms to which they are attached, there is formed a C₅₋₇ ring;
- 15 Het is a 5- or 6-membered heterocyclic ring containing 2 or 3 nitrogen atoms optionally substituted by =O, =S or a C₁₋₄alkyl group;
- 15 X is an alkylene chain of 1 to 4 carbon atoms optionally substituted 25 by oxo;
- 15 Y is a C₁₋₄alkyl group optionally substituted by hydroxy;
- 15 Z is C₁₋₆alkylene or C₃₋₇cycloalkylene;
- 15 m is 0 or 1; and
- 15 n is 0 or 1, where the sum total of n+m is 1 or 2;
- 30 or a pharmaceutically acceptable salt thereof.

2. A compound as claimed in claim 1 wherein R¹ is hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halogen or CF₃.


3. A compound as claimed in claim 1 or claim 2 wherein R² is
5 hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halogen or CF₃.

4. A compound as claimed in any one of claims 1 to 3 wherein R³ is hydrogen, fluorine, chlorine or CF₃.

10 5. A compound as claimed in any one of claims 1 to 4 wherein m is 1.

6. A compound of the formula (Ia) or a pharmaceutically acceptable salt thereof:

15



(Ia)

wherein A¹ is fluorine or CF₃;

A² is fluorine or CF₃;

20 A³ is fluorine or hydrogen;


and R⁶, R⁷, X, Y, Z, Het, m and n are as defined in claim 1.

7. A compound as claimed in any one of claims 1 to 6 wherein Y is a C₁₋₄alkyl group.

5 8. A compound as claimed in any one of claims 1 to 7 wherein X is CH₂, CH(CH₃) or CH₂CH₂.


9. A compound as claimed in any one of claims 1 to 8 wherein the group Het-ZN(O)_mR⁶R⁷ is selected from:

10



10. A compound as claimed in claim 9 wherein the group Het-ZN(O)_mR⁶R⁷ is:

15



11. A compound as claimed in any one of claims 1 to 10 wherein Z
20 is CH₂ or CH₂CH₂ and NR⁶R⁷ is amino, methylamino, dimethylamino, diethylamino, azetidinyl, pyrrolidino and morpholino.

12. A compound selected from:

- 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino(N-oxide)methyl)-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine;
- 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylaminomethyl)-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine N-oxide;
- 5 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(5-(N,N-dimethylamino(N-oxide)methyl)-1,2,3-triazol-4-yl)methyl-3-(S)-(4-fluorophenyl)morpholine N-oxide;
- 10 3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-methylthio-5-(trifluoromethyl)phenyl)ethoxy)-4-(5-pyrrolidinomethyl-1,2,3-triazol-4-yl)methylmorpholine N-oxide;
- 15 3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-methylthio-5-(trifluoromethyl)phenyl)ethoxy)-4-(5-pyrrolidino(N-oxide)methyl-1,2,3-triazol-4-yl)methylmorpholine N-oxide;
- or a pharmaceutically acceptable salt thereof.

12. A compound as claimed in any preceding claim for use in therapy.

20

13. A pharmaceutical composition comprising a compound as claimed in any one of claims 1 to 11 in association with a pharmaceutically acceptable carrier or excipient.

25

14. The use of a compound as claimed in any one of claims 1 to 11 for the manufacture of a medicament for the treatment or prevention of a physiological disorder associated with an excess of tachykinins.


30

15. The use of a compound as claimed in any one of claims 1 to 11 for the manufacture of a medicament for the treatment or prevention of pain, inflammation, migraine, emesis or postherpetic neuralgia.

16. A process for the preparation of a compound as claimed in claim 1 which comprises:

oxidation of one or both of the nitrogen atoms drawn in formula (II):

5



said process being followed, where necessary, by the removal of any protecting group where present;

10 and when the compound of formula (I) is obtained as a mixture of enantiomers or diastereoisomers, optionally resolving the mixture to obtain the desired enantiomer;

and/or, if desired, converting the resulting compound of formula (I) or a salt thereof, into a pharmaceutically acceptable salt thereof.



The
Patent
Office

62

Application No: GB 9613003.4
Claims searched: 1-16

Examiner: Roy Honeywood
Date of search: 5 September 1996

Patents Act 1977
Search Report under Section 17

Databases searched:

UK Patent Office collections, including GB, EP, WO & US patent specifications, in:

UK Cl (Ed.O): C2C

Int Cl (Ed.6): C07D

Other: ONLINE: CAS

Documents considered to be relevant:

Category	Identity of document and relevant passage	Relevant to claims
	None	

- | | |
|---|--|
| X Document indicating lack of novelty or inventive step | A Document indicating technological background and/or state of the art. |
| Y Document indicating lack of inventive step if combined with one or more other documents of same category. | P Document published on or after the declared priority date but before the filing date of this invention. |
| & Member of the same patent family | E Patent document published on or after, but with priority date earlier than, the filing date of this application. |

